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1. Abbreviations 
 
aa   amino acids 
Ala   alanine 
Arg   arginine 
Asn   asparagine 
ATTC   American Type Culture Collection 
BALB/c  “Bagg Albino” inbred mice strain 
˚C   degree Celsius 
cDNA   complementary deoxyribonucleic acid  
c-ELISA  competitive enzyme-linked immunosorbent assay 
Cys   cysteine 
d-ELISA  direct enzyme-linked immunosorbent assay 
dH2O   distilled water 
EAV   equine arteritis virus 
EDTA   ethylene-diamine tetra-acetic acid 
ELISA   enzyme linked immunobsorbent assay 
EVA   equine viral arteritis 
g   relative centrifugal force 
Gln   glutamine 
Gly   glycine 
Gp   glycoprotein 
h   hour 
His   histidine 
IFA   immunofluorescense assay 
Ig   immunoglobulin 
Ile   isoleucine 
kDa   kilodalton 
l    liter 
Leu   leucine 
Lys   lysine 
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M   Mol 
MAb   monoclonal antibody 
MEM   minimal essential medium 
Met   methionine   
min   minute(s) 
ml   milliliter 
MLV   modified live virus 
M.O.I.   multiplicity of infection 
mRNA   messenger ribonucleic acid  
nsp   non structural protein 
OD   optical density 
OPD   o-phenyldiamine  
ORF   open reading frame 
PCR   polymerase chain reaction  
PEG   polyethylene glycol 
PFU   plaque forming units 
pH   pondus hydrogenii (measurement of hydrogen ion concentration) 
Phe   phenylalanine 
Pro   proline 
qs   quantitate to 
RNA   ribonucleic acid 
rpm   rounds per minute 
RT-PCR  reverse transcription-polymerase chain reaction 
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
Ser   serine 
sg   subgenomic 
T   temperature 
Thr   threonine 
TRS   transcription regulating sequence 
Tyr   tyrosine 
µl   microliter 
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2. Introduction  
 
Descriptions of the disease equine viral arteritis can be found as far back as the 
late eighteenth and early nineteenth century, where it is referred to as “pinkeye”, 
“infectious or epizootic cellulites”, “influenza erysipelatosa”, “Pferdestaupe”, 
“Rotlaufseuche” and “equine influenza” (Bergmann, 1913; Burki and Gerber, 1966; 
Clark, 1892; Hofer and Steck, 1976; Mumford, 1985; Plateau and Jacquet, 1888). The 
disease, which affects all equines including horses, donkeys and mules, is caused by 
equine arteritis virus (Hofer and Steck, 1976; Newton et al., 1999; Paweska and Barnard, 
1993; Paweska, 1994). The virus was first isolated in 1953, during an extensive outbreak 
of respiratory disease and abortion on a Standardbred breeding farm near Bucyrus, Ohio 
USA (Doll et al., 1957). After isolation of the virus from the lungs of an aborted fetus and 
the description of characteristic vascular lesions, EVA was distinguished from equine 
influenza (equine influenza virus) and equine rhinopneumonitis (equine herpes virus), 
which cause similar clinical syndromes (Doll et al., 1957a). 
Today EAV is geographically wide spread (Chirnside, 1992) and most European 
and North American countries have EAV-seropositive animals, due to international 
movement of horses for breeding or competition (Hullinger et al., 2001; McCollum and 
Bryans, 1973; McKenzie, 1988; Timoney, 1992). Over the last years, there has been an 
apparent increase in the number of confirmed outbreaks of EVA worldwide, suggesting 
that EVA is an emerging disease (Timoney, 1986). Tests of randomly selected horse sera 
in Germany showed an increase of EAV antibodies from 1.8% in 1987/1988 to 24.8% in 
1994 (Kaaden et al., 1996). EU Community measures were confined to import 
restrictions for carrier stallions from non-EU countries. In March 1995 the German State 
Veterinary Service changed the status of EVA and it was declared as a notifiable disease 
(Eichhorn et al., 1995; Kaaden et al., 1990). This reflects an international trend, triggered 
by the significant economic impact EVA outbreaks can have, especially in the horse 
breeding and racing industries. 
Reliable testing is the key to continued safe movement of horses for breeding and 
athletic competition. The current officially recognized serological test is the serum 
neutralisation test, which is highly specific but suffers from the disadvantages that it is 
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slow and time consuming. ELISA-based serological assays offer considerable theoretical 
advantages for the serological testing of horses for previous exposure to EAV. Thus the 
development of a more convenient and rapid test for serologic diagnosis of EAV 
infection of horses has been a consistent research goal in recent years (Balasuriya et al., 
2002; Chirnside et al., 1995a; Hedges et al., 1998; Inguiez et al., 1998; Kondo et al., 
1998).   
The objective of this study was to further evaluate the serological response of 
horses to EAV infection by comparing data obtained with known EAV-positive and 
negative horse sera and several competitive ELISAs to different EAV structural proteins 
(E, GL, M and N) and non structural proteins (nsp1). This required that MAbs first be 
produced to the M and nsp1 proteins of EAV. 
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3. Literature review 
 
3.1 Equine arteritis virus  
3.1.1 Classification 
Equine arteritis virus was first designated as a ribolipovirus and grouped into the 
“hemoviruses” along with hog cholera and bovine viral diarrhea viruses (Burki, 1965; 
Burki and Gerber, 1966). This group of viruses is not arthropod-transmitted, although 
Breese and McCollum et al. (1970) initially considered EAV to be an arbovirus based on 
its morphological characteristics. 
During further characterization some morphological and physicochemical 
properties similar to alphaviruses (Horzinek et al., 1971; Hyllseth et al., 1970; Maess et 
al., 1970; Magnusson et al., 1970) and flaviviruses (Burki, 1970; Burki et al., 1972; 
Hyllseth, 1970a) were identified. Two comparative studies found that EAV was distinct 
from viruses in those two groups (Horzinek, 1973; Horzinek, 1973a; Horzinek, 1981). On 
the basis of morphologic criteria such as size, an isometric core and the presence of an 
envelope, it was proposed that EAV be classified as a non-arthropod-borne togavirus 
along with the pestiviruses and rubiviruses, lactate dehydrogenase-elevating virus (LDV), 
simian hemorrhagic fever virus (SHFV) and cell fusion virus (Porterfield et al., 1978). 
EAV, LDV and SHFV were subsequently assigned in 1984 to a new genus arterivirus 
within the family Togaviridae (Westaway et al., 1985). However, the structural proteins 
of LDV and EAV were known to differ from those of the togaviruses (Plagemann, 1996; 
van der Zeijst et al., 1987). Sequence analysis as well as characterization of the 
replication of these viruses in the last decade showed that EAV is evolutionarily related 
to viruses from the coronavirus-like superfamily (den Boon et al., 1991; Seybert et al., 
2000; Snijder et al., 1993). In 1996, during the 10th International Congress of Virology 
(Jerusalem), EAV, LDV, SHFV and porcine reproductive and respiratory syndrome virus 
(PRRSV; Meulenberg et al., 1994), were included in the family Arteriviridae (Cavanagh, 
1997). 
The basis for the classification of arteriviruses as an independent family was 
their distinct biological properties, including their unique structural proteins, the virion 
morphology, and their ability to establish persistent infections. Furthermore sequence 
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studies revealed an unexpected relationship with members of the coronavirus family at 
the level of genome organization and expression (den Boon et al., 1991; de Vries et al., 
1990; Godney et al., 1993; Kuo et al., 1992; Meulenberg et al., 1993; Murtaugh et al., 
1995; Thiel et al., 1993). The common link is reflected in the genome expression of both 
families, which includes the generation of a nested set of sg mRNAs. This fact led to the 
establishment of the order Nidovirales, which includes the arterivirus and coronavirus 
families (Cavanagh, 1997). 
 
3.1.2 Morphology and physicochemical properties 
EAV is an enveloped single-stranded positive sense RNA virus (Horzinek, 1981; 
Maess et al., 1970; Magnusson et al., 1970). The virion is a spherical, 50-65 nm particle 
with a 30-35 nm icosahedral core with a lipid envelope (Horzinek et al., 1971). The 
envelope includes 12-15 nm diameter ring-like structures (Hyllseth, 1973) and its 
membrane is derived from a pre-Golgi compartment (Plagemann, 1996). The morphology 
of extracellular virus particles was established by negative and positive staining of 
purified virus preparations (de Vries, 1994; Horzinek et al., 1971; Hyllseth, 1973; Maess 
et al., 1970). The reported size of the virus particle varies from 50 to 65 nm, depending 
on the purification and staining method used (Burki, 1966; Maess et al., 1970 Maess et 
al., 1970a; Magnusson et al., 1970). De Vries (1994) demonstrated tiny “spikes” on the 
viral surface and showed a small fraction of virus particles to contain two nucleocapsids 
by using cryo-electron microscopy.  
The buoyant density of EAV has been determined using sucrose, cesium chloride 
and potassium tartrate gradients (Hyllseth, 1970; Hyllseth, 1973; Maess et al., 1970).  
Depending on the substrate used, the infectivity peak varied from 1.155 – 1.19 g/cm3 
(Iwashita ad Harawasana, 1987; Maess et al., 1970; van der Zeijst and Horzinek, 1975; 
Zeegers et al., 1976). The sedimentation coefficient of EAV particles is approximately 
224 S +/- 8, whereas the nucleocapsid sediments at 158 S (van der Zeijst and Horzinek, 
1975). 
The EAV virions are highly unstable at a pH other than 6 to 7.5, or in solutions 
that contain low concentration of non-ionic detergents (Burki, 1966; Konishi et al., 1975). 
The virus remains viable during prolonged storage at -20 to -70°C (Crawford and 
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Henson, 1973). EAV quickly loses its infectivity when stored at temperatures of 4°C and 
higher. As shown for the Bucyrus and Bibuna strains (Konishi et al., 1975), incubation at 
37°C or 50°C for 30 minutes had no dramatic effects on the virus infectivity whereas 
incubation at 60°C for 30 minutes reduced the virus titre by 4.0 to 5.75 log 10ID50.      
Reports on the effect of trypsin on EAV are controversial. In a study by Burki and 
Gerber (1966) the virus was reported to be resistant, whereas Konishi et al. (1975) found 
a reduction of virus titre after trypsin treatment. EAV is inactivated by ether and 
chloroform (Burki, 1965; Doll et al., 1957a), sodium deoxylcholate 1 mg/ml (Konishi et 
al., 1975) and by incubation with phospholipase C for 30 minutes at 37°C (Hyllseth, 
1973). The envelope can readily be removed by treatment with 1% Triton X-100 or other 
non-ionic detergents, which leaves pure nucleocapsid preparations (Horzinek et al., 
1971). 
 
3.1.3 Growth in cell culture 
EAV, in contrast to the extreme cell type specificity of the other members of the 
Arteriviridae family, is not fastidious in its growth in vitro. The virus replicates well in 
primary cultures of endothelial, kidney, ovary and dermal cells (Burki, 1965; Klavano, 
1987; McCollum et al., 1961; McCollum et al., 1962; McCollum et al., 1962a; 
Shinagawa et al., 1976; Wilson et al., 1962), as well as a variety of cell lines such as baby 
hamster kidney (BHK-21; Hyllseth, 1969; Maess et al., 1970), rabbit kidney (RK-13; 
McCollum et al., 1970), rhesus monkey kidney (LLC-MK2; Breese and McCollum, 
1970), African green monkey kidney (VERO) and hamster lung cells (HmLu; Konishi et 
al., 1975). The appearance of the cytopathic effect (CPE) and titer of virus produced by 
different cell lines varies significantly. Rounding, vacuolation, increased optical density, 
refraction and detachment from the supporting surface characterize the CPE exhibited by 
EAV-infected cells. The CPE caused by EAV is used for quantity titration of virus in 
infected tissue cell culture and tissue culture fluids by endpoint titration dilution assay 
and plaque assays. The results obtained can depend on the passage history of the cells 
(Bagust, 1972; Fukunaga et al., 1981; Hyllseth, 1969; Konishi et al., 1975; Maess et al., 
1970; McCollum, 1970; Radwan and Burger, 1973; van Berlo et al., 1980; Wilson et al., 
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1962). Moore et al. (2002) showed that equine pulmonary endothelial cells can provide a 
relevant model for the in vitro characterization of the virulence determinants and 
pathogenesis of EAV.   
The kinetics of EAV adsorption to different cell lines at different temperatures has 
been described (Higgins, 1993; Hyllseth, 1969; Radwan et al., 1973). Experiments have 
shown that approximately 50% of the inoculated plaque forming units of virus adsorb to 
BHK-21 cells after 1h of incubation at 37°C and almost 100% after 2h. One step growth 
experiments have shown that the first release of progeny virus is after 6 to 8h and peaks 
between 12 and 20h post infection (Inoue et al., 1975; Tsukamoto et al., 1982; van Berlo 
et al., 1982; van Berlo et al., 1986; van Berlo et al., 1986a), often with titers that exceed 
108 TCID50 / ml. In RK-13 cells progeny virus appears at 8h after infection when 
incubated at 37°C, and a second round of replication begins at 18 to 24 h and peaks at 36 
to 48h with a titer of  >107 TCID50/50 µl (Balasuriya et al., 1993; de Vries et al., 1994).   
 
3.1.4 Molecular biology 
Viral genetics and replication 
The first indication that EAV is an RNA virus was evidenced by the ability of 5-
iodo-2-deoyuridine to inhibit viral replication (Burki, 1965; Burki, 1966). Additional 
evidence was provided by the labelling of the viral genome with [3H]uridine (Breese et 
al., 1971; Rawanda et al., 1973). Van der Zeijst and Horzinek (1975) demonstrated that 
the EAV genome is an infectious, single-stranded RNA molecule with an estimated 
molecular weight of 4x106, as determined by polyacrylamide-agarose-gel electrophoresis 
(PAGE) and a S20,W value of 48 in isokinetic sucrose gradient in 0.1 M saline. RNA 
extracted from purified virus was infectious, but following RNase treatment the 
infectivity of the extracted RNA was completely abolished. Actinomycin D did not 
inhibit EAV replication (Van der Zeijst and Horzinek, 1975).  These studies indicated, 
therefore, that EAV genomic RNA is positive sense.   
The EAV genome includes 12,687 bases and contains at least nine open reading 
frames (ORFs; den Boon et al., 1991). ORFs 1a and 1b are located within the 9.7 kb at 
the 5’end of the genome and encode the viral replicase (van der Meer et al., 1998; Snijder 
et al., 1994; Snijder et al., 1993a). The ORFs 2a, 2b, 5, 6, and 7 encode the five structural 
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proteins (see 3.1.5), E, Gs, GL, M and N, whereas ORFs 3 and 4 encode two poorly 
characterised glycoproteins, Gp3 and Gp4 (Chirnside et al., 1993; deVries et al., 1992). 
Attachment and entry 
The attachment and entry pathway of Arteriviridae is not yet fully characterized. 
The M and GL proteins were assumed to serve the viral targeting function. Studies using 
an infectious cDNA clone of PRRSV with a chimeric M protein of other arteriviruses 
showed that the surface structures composed by arterivirus M and GL ectodomains do not 
determine viral tropism (Verheije et al., 2002). Arteriviruses can replicate in several cell 
lines that are not susceptible to infection with virus particles, after transfection with 
genomic RNA (Inada et al., 1991; Meulenberg et al., 1996). This finding, together with 
the fact that certain cell lines that are not susceptible to LDV infection become 
susceptible after infection with murine leukemia virus (Inada and Yamazaki, 1991), 
suggests that cell tropism is determined by the presence of an as yet unidentified receptor 
on the cell surface. Studies on PRRSV have shown that low pH appears to be required for 
virus entry, which most likely occurs through the standard endocytic route (Kreutz et al., 
1996). The entry was blocked by cytochalasin D (Glaser et al., 1997), a compound that 
inhibits receptor-mediated endocytosis.  
Genome replication 
The replication cycle of EAV occurs entirely in the cytoplasm of infected cells 
(see Figure 1). A genome-length negative strand is generated that serves as the template 
for genome replication. Furthermore, nested sets of complementary sg negative strands 
and sg mRNAs are generated (Snijder and Meulenberg, 1998). The transcripts in each set 
are both 5’- and 3’- coterminal with each other and with the corresponding genome-
length RNA. There is little known about the signals involved in the genome replication. 
Recently, natural and synthetic defective interfering RNAs have been generated for EAV 
(Molenkamp et al., 2000). Those RNAs invariably require at least 300 nucleotides from 
the 3’ and 5’ genome termini for efficient replication. The interaction of the signals with 
the host proteins or viral proteins is largely uncharacterized. It appears that four proteins, 
which have yet to be identified, interact with transcripts representing the corresponding 
region of the EAV negative strands, suggesting the involvement of a common set of host 
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factors in the initiation of arterivirus positive-stranded RNA synthesis (Hwang and 
Brinton, 1998). 
 
 
 
Figure 1: Overview of the life cycle of EAV 
The genome organization and the replicase cleavage sites (arrowheads) are shown at the 
top of the figure. At the right the nested set of subgenomic (sg) mRNAs and their 
common leader sequence (L) are illustrated. DMV, double membrane vesicle; ER, 
endoplasmic reticulum; NC, nucleocapsid; PM, plasma membrane. (Snijder and 
Meulenberg, 2001)   
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Subgenomic mRNA transcription 
EAV and other members of the Arteriviridae characteristically generate a nested 
set of sg mRNAs during their replication cycle from which the genes in the 3’ end of the 
genome are expressed. The mRNAs have a 5’ terminal leader sequence that is derived 
from the 5’ end of the genome, and they are 3’ coterminal. Based on studies of EAV 
replication, it was postulated that arterivirus sg mRNAs are synthesized by a 
discontinuous transcription mechanism (den Boon et al., 1995). The presumed common 
ancestry of the arterivirus and the coronavirus replicase genes supports this concept. A 
substantial number of models for nidovirus sg mRNA synthesis have been proposed. 
Recently, a direct proof of base pairing between the positive leader transcription-
regulating sequence (TRS) and the negative body TRS was obtained from reverse genetic 
studies using an EAV infectious cDNA clone (van Maarle et al., 1999). The stability of 
this duplex was shown to be a crucial factor in the synthesis of subgenomic mRNA of 
arteriviruses (Pasternak et al., 2003).  Introducing site-specific mutations in the positive 
leader TRS can be compensated by introduction of the same mutations in the positive 
body TRS. The model of discontinuous negative-stranded synthesis was supported by 
TRS sequences found in mRNAs generated by TRS mutants with partial transcription 
activity (van Maarle et al., 1999).  
Translation and posttranslational processing 
The first step in EAV replication is the translation of the virus genome that yields 
two large replicase polyproteins, ORF1a and ORF1b protein. A ribosomal frame shift is 
required for the translation of ORF 1b, immediately before ORF 1a translation is 
terminated (den Boon et al., 1991). Two signals that promote this event are contained in a 
region overlapping ORFs 1a and 1b. This region is a so-called slippery knot sequence, 
which is the actual frame shift site, and a downstream RNA pseudoknot structure. A 
frame-shifting efficiency of 15 to 20% was observed, using a reporter gene construct for 
EAV (den Boon et al., 1991). In the post-translational phase the ORF 1b polyprotein is 
cleaved at least ten times by three different ORF 1a-encoded proteases. In combination 
with the ribosomal frame shift, this leads to the generation of 12 processing end products 
and a large number of processing intermediates. The end products are named non-
structural proteins 1 to 12, nsp1-8 are generated by ORF 1a and 10-12 by ORF 1b. Nsp9 
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consists of a small, ORF 1a-encoded N-terminal domain, and a large C-terminal part that 
is encoded by the 5’-proximal region of ORF 1b. The EAV protease domains are located 
in nsp1 (29kDa), nsp2 (61kDa), and nsp4 (21kDa). These proteases and their cleavage 
sites are well conserved (Snijder et al., 1995). Both, nsp1 and 2 contain a cysteine 
autoprotease domain that mediates, probably exclusively in cis, their rapid release from 
the polyprotein. The N-terminal replicase subunit, nsp1, was shown to be dispensible for 
genome replication but absolutely required for sg RNA transcription (Tijams et al., 
2001). The nsp1 protease has been characterized as a papain-like cysteine protease (PCP; 
Snijder et al., 1992; denBoon et al., 1995a), with residues Cys-164 and His-230 forming a 
putative catalytic dyad in EAV. Nsp1 consists of two papain-like protease domains and a 
predicted N-terminal zinc finger (Tijams et al., 2001). The nsp2 cysteine protease is an 
unusual cysteine protease showing similarities in the amino acid sequence to papain-like 
and chymotrypsin-like proteases (Snijder et al., 1995). Nsp4, a serine protease, is the 
prototype of the 3C-like serine proteases, a novel group of chymotrypsin-like enzymes 
(Snijder et al., 1996). The EAV replicase subunits localize to the perinuclear region of the 
infected host cells, where they are associated with the intracellular membranes, 
exclusively or predominantly with those of the endoplasmatic reticulum (Balasuriya et 
al., 2000; Pederson et al., 1999; van Dinten et al., 1996; van Dinten et al., 1997). This 
complex has been shown to be the site of de novo viral RNA synthesis by electron 
microscope studies (Balasuriya et al., 2000; Faaberg and Plagemann, 1995). Parts of nsp1 
are the only exception regarding the perinuclear localization of replicase subunits. 
Fractions of nsp1 have been found in the host cell nucleus, especially during the earlier 
stages of infection (Tijams et al., 2002). The fact that an autoimmune response against 
Golgi-antigens has been reported in mice after infection with EAV, may offer an 
approach to determine the mechanism by which such responses develop and become of 
biological importance (Weiland and Weiland, 2002). After infection with EAV, host cell 
membranes are modified into vesicular double membrane structures that carry the 
Arteriviridae replication complex (Balasuriya et al., 2000; Porterfield et al., 1978). 
Predictions relating to the functions of the ORF 1b encoded replicase subunits are largely 
derived from comparative sequence analysis. An in vitro assay demonstrated that nsp10 
has a duplex unwinding activity (Senne et al., 1985). ORF 1b encodes two additional 
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conserved domains that appear to be unique to nidoviruses: a conserved domain in nsp11 
and a Cys-His-rich domain in the N-terminal region of nsp10, upstream of the helicase.  
A replacement of Ser-2429 by Pro in nsp10, rendered the EAV full-length cDNA clone 
non-infectious owing to an almost complete block of sg mRNA transcription (Crawford 
et al., 1973; van Dinten et al., 1997) The mutant replicated its genomic RNA efficiently, 
showing that replication and sg mRNA transcription are distinct processes.                
 
 
3.1.5 Structural proteins 
After a number of conflicting, often contradictory reports, research has shown that 
arteriviruses possess six or seven structural proteins, which is unusually large compared 
to other positive stranded RNA viruses (Chirnside, 1992; de Vries et al., 1992; Dobbe et 
al., 2001; hyllseth, 1973; Iwashita et al., 1987; van Berlo et al., 1986; Zeegers et al., 
1976). The E protein of EAV (7kDa) is encoded by ORF 2a, a gene conserved in all 
arteriviruses. The E protein is a small, hydrophobic nonglycosylated protein that is 
thought to be an integral membrane protein with an uncleaved signal anchor sequence in 
the central part of the molecule (de Vries et al., 1992; Snijder et al., 1999). 
The ORF 2b encoded minor envelope protein was designated Gs (Gp2; Lepage et 
al., 1996). It is a typical class I membrane protein of 25kDa that contains complex type 
N-glycans when incorporated into virions. It appears to be indispensable for virion 
replication, since its deletion rendered the EAV full-length cDNA clone non-infectious 
(van Dinten et al., 1997). The Gs protein occurs in infected cells in four monomeric 
conformation as well as disulfide linked homodimers. Only the homodimers are 
incorporated into virus particels. The fact that the protein is retained in the ER upon 
individual expression in vivo (de Vries et al., 1995a; Meulenberg and Petersen-den 
Besten, 1996) indicates that it probably requires other structural proteins and/or virus 
assembly for transport from the ER to the Golgi complex.  
The major glycoprotein (GL; 30-42kDa) of EAV is N-glycosylated and includes 
255 amino acids; it is also referred to as GP5. The putative ectodomain is 95 residues 
long and possesses a single N-linked polylactosamine side chain (de Vries et al., 1992). 
Some strains of EAV however, have an additional N-glycan chain (Glaser et al., 1995). 
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The GL ectodomain is an important antigen that is recognized by neutralizing and non-
neutralizing antibodies in the horse (Chirnside et al., 1995; Chirnside et al., 1995a), and it 
may function in both receptor binding and membrane fusion (de Vries, 1994). 
Neutralization resistant variants (escape mutants) of EAV contained minor mutations or 
even substantial deletions in this region of ORF 5 (Balasuriya et al., 1995a; Balasuriya et 
al., 1999a; Larsen et al., 2001). Sequence analyses of the GL protein have shown that 
there is a high diversity amongst field and laboratory strains of EAV (Balasuriya et al., 
1995a; Larsen et al., 2001). The number of glycosylation sites differs between strains 
(Glaser et al., 1995).  
The major envelope protein (M; 16kDa; 162 aa) is the most conserved structural 
protein of the arteriviruses. It is encoded by ORF 6 and so also is referred to as GP6. It is 
a hydrophobic polypeptide and the N-terminal half contains three potential membrane-
spanning regions that may imply a NexoCendo orientation (Snijder and Meulenberg, 1998). 
The poor immunogenicity of the M protein is probably explained by the fact that only a 
short stretch of only 10 to 18 aa residues is thought to be exposed at the virion surface. 
Recently Jeronimo and Archambault (2002) discovered that the C-terminal portion of the 
M protein that includes aa 88 to 162, is recognized by EAV specific antisera. One of the 
membrane-spanning fragments is thought to function as a signal sequence. Little is 
known about the function of the M protein, although it probably plays an important role 
in virus assembly and budding, as shown for coronaviruses. The M protein accumulates 
in the endoplasmatic reticulum, where it forms disulfide-linked heterodimers with the GL 
protein (Crawford et al., 1996; Faaberg et al., 1995). A single Cys residue (Cys-8) in the 
short N-terminal ectodomain of the M-Protein ectodomain is involved in the formation of 
an intermolecular disulfide bridge with a Cys-34 residue in the GL ectodomain (Snijder et 
al., 2003).  
The GL-M heterodimers are essential for infectivity and are transported to the 
Golgi complex (de Vries et al., 1995) and incorporated into the virus particle at some 
point during this process. Disulfide-linked M protein homodimers were observed in cells 
infected with EAV, but these were not incorporated into virions. The M and N proteins of 
EAV are highly conserved (Balasuriya et al., 1995; Chirnside et al., 1994; Glaser et al., 
1995; Hedges et al., 1996). 
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The nucleocapsid protein (N; 14kDa) is a small, phosphorylated, basic protein of 
110 amino acids, and is also referred to Gp7. It is expressed abundantly in infected cells 
and constitutes about 20-40% of the protein content of the virion. The N protein interacts 
with genomic RNA during assembly of the nucleocapsid, although the important regions 
have not yet been defined. Sera from some EAV-infected horses contain high titres of 
anti-N protein antibodies. The N protein therefore, might provide a suitable antigen for 
EAV-specific serological tests (Chirnside et al., 1995b; Kehyar et al., 1997).       
The EAV Gp4 protein is a class I integral membrane protein of 28 kDa with three 
functional N-glycosylation sites and with little of its carboxy terminus exposed. Gp3, on 
the other hand, is a heavily glycosylated protein whose hydrophobic amino terminus is 
not cleaved off. It is an integral membrane protein anchored by either or both of its 
hydrophobic terminal domains and with no parts detectably exposed cytoplasmically. 
Both proteins localize in the ER when expressed independently and in EAV infected 
cells. But only a small fraction of the synthesized Gp3 and Gp4 proteins end up in 
virions. Most of the oligosaccharides of these virion glycoproteins are biochemically 
mature (Snijder et al., 2003; Wieringa et al., 1985).  
The specific functions of the envelope proteins of EAV and the other arteriviruses 
have yet to be fully characterized, but it has been shown by reverse genetics that E, GP2, 
GP3, GP4, GP5 and the M-protein are all essential for the production of infectious 
progeny virus (Meulenberg and Petersen-den Besten, 1996; Molenkamp et al., 2000a; 
Snijder et al., 2003). 
 
3.1.6 Neutralization determinants of the virus 
 A variety of EAV-specific neutralizing monoclonal antibodies and peptide-
specific antisera have recently been developed (Balasuriya et al., 1993; Balasuriya et al., 
2001; Chirnside et al., 1988; Cho et al., 2000; Deregt et al., 1994; Glaser et al., 1995; 
Kondo et al., 1994; Tobiasch et al., 2001; Weiland et al., 2000; Yamaguchi et al., 1997). 
All neutralizing MAbs consistently recognize the major envelope glycoprotein (GL), as 
determined by western immunoblotting, immunoprecipitation and ELISA assays. Amino 
acid residues 19 through 116 of the GL envelope glycoprotein are predicted to constitute 
the hydrophilic ectodomain (de Vries et al., 1992; de Vries, 1994).  By subcloning and 
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expression of the GL envelope glycoprotein, Chirnside et al. (1995) mapped an immuno-
dominant epitope between amino acids 55 through 98.  In addition, they also 
demonstrated that a bacterial fusion protein covering this region and a GL specific 
synthetic peptide (residues 75 through 97) induced EAV-neutralizing antibodies in horses 
(Chirnside et al., 1995a).  Based on these findings, it was concluded that amino acids 54 
through 99 in the putative hydrophilic ectodomain of the GL protein were responsible for 
the virus neutralizing response in horses. Balasuriya et al. (1995) showed that amino 
acids 99 to 104 were critical to expression of three interactive neutralization epitopes on 
the GL protein. Furthermore mice immunized with a 20-amino-acid GL -specific synthetic 
peptide, which spans amino acids 93 to 112 of the GL protein, developed antibodies that 
neutralized EAV, confirming that this region is an important neutralization determinant 
of EAV (Balasuriya et al., 1997). Glaser et al. (1995) demonstrated that amino acid 
residues 96, 99, 100 and 113 are critical for virus neutralization. Most of the major 
neutralization epitopes recognized by different laboratories fall within the V1 variable 
region (amino acids 61 to 121) of the GL protein (see below).   
 
3.1.7 Genetic and phenotypic variation 
 Many RNA viruses do not exist as a single genotype of defined sequence; rather 
they are genetically heterogeneous and exist as a population of related genomes 
(Domingo et al., 1980; Domingo, 1989; Domingo et al., 1993; Fukunaga e al., 1984; 
Westkott et al., 1995). In such populations, even under natural conditions, a particular 
genome may be selected over others altering the phenotype of the virus, the so-called 
virus “quasi-species” (Baranowski et al., 1999; Domingo et al., 1985; Domingo and 
Holland, 1988; Domingo, 1992; Domingo et al., 1992; Holland et al., 1992; Labrie and 
Moineau, 2002). 
 Although there is only one serotype of EAV, genetic variation amongst field 
strains of the virus has been demonstrated by RNase T1 oligonucleotide fingerprinting 
(Murphy et al., 1988; Murphy et al., 1992; Stadejek et al., 1999).  Furthermore, oligo-
nucleotide fingerprinting of sequential isolates from the same persistently infected 
stallion revealed an ongoing variation of 6 to >20% (Murphy et al., 1992a). Hedges et al. 
(1999) amplified EAV genomes from semen of two Thoroughbred stallions that were 
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infected during the 1984 outbreak of EVA and subsequently became long-term carriers. 
Sequence analysis of ORFs 2 through 7 showed a variation of approximately 1% per 
year. Nucleotide sequence homologies and phylogenetic analysis of the M and N protein 
genes (ORFs 6 and 7) of ten EAV isolates demonstrated strain variation and possible 
RNA recombination between EAV isolates (Chirnside et al., 1994).  Sugita et al. (1994) 
showed the existence of distinct geographic groupings of EAV isolates by sequence 
analysis of the M protein gene of viruses from Europe and the United States.  A 
difference in restriction fragment length polymorphism (RFLP) pattern of ORF 6 of 
seven EAV isolates and the modified live vaccine virus has been described (Sekiguchi et 
al., 1995).  The genetic variation and phylogenetic relationship of ORF 5 of 3 different 
laboratory strains of the original Bucyrus strain of EAV, the modified live virus vaccine 
(ARVAC®, Fort Dodge Laboratories), and 18 field isolates of EAV from North America 
and Europe have been reported (Balasuriya et al., 1995a).  The field isolates and 
laboratory strains of EAV compared in this study segregated into 4 phylogenetic groups 
that include two North American (NA1 and NA2) and two European (E1 and E2) groups.  
In addition, sequence data from individual European and North American isolates 
indicate movement of viruses between the two continents. Comparative analysis of 
deduced amino acid sequences of the GL protein of the viruses identified three distinct 
variable regions (V1 [aa 61-121], V2 [aa 141-178], and V3 [aa 202-222]), a putative 
signal sequence (S[aa 1-18]), and four conserved regions (C1[aa 19-60], C2 [aa 122-140], 
C3 [aa 179-201], and C4 [aa 223-255]; Balasuriya et al., 1995a).  The same viruses were 
used by Hedges et al. (1996) to study the genetic variation of ORF 2 of EAV, which 
encodes the minor envelope glycoprotein (GS) of the virus.  The data indicated that the 
GS protein was highly conserved between isolates, considerably more so than the GL 
protein encoded by ORF 5.  Phylogenetic analysis of ORF 2 and ORF 5 gave similar but 
not identical results indicating that different selective pressures are exerted on the two 
proteins.  Sequence analysis of ORF 2 and 5 also suggest that EAV behaves as a “quasi-
species” in nature (Hedges et al., 1999; Magnusson et al., 1970; Stadejek et al., 1999). 
There does appear to be minor antigenic variation amongst field strains of EAV, based on 
complement fixation test results and the requirement for complement for effective virus 
neutralization (Fukunaga and McCollum, 1977; Fukunaga et al., 1993; Fukunaga et al., 
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1994; Golnik et al., 1986; McCollum, 1976). All field strains are neutralized by equine 
polyclonal antiserum to the virulent Bucyrus strain of EAV. Comparison of structural 
protein sequences has shown that the M and N proteins are more conserved than the 
glycoproteins (Balasuriya et al., 1993; Balasuriya et al., 1995; Glaser et al., 1995). In 
addition, the ORF 5 protein sequence is more variable (89.8-99.6% identity) than the 
ORF 2 protein sequence (Stadejek et al., 1999). Geographically and temporally distinct 
EAV isolates also vary in their virulence and in their abortigenic potential (Balasuriya et 
al., 1999; Burki, 1970; McCollum and Swerczek, 1978; McCollum, 1996; McCollum and 
Timoney, 1996a). Timoney et al. (1987a) reported in 1987 that virus strains shed in the 
semen of long-term carrier stallions are of low virulence and cause only asymptomatic 
infection in mares bred to these stallions. The clinical severity of EVA differs between 
outbreaks, and it can be difficult to isolate viruses from nasal swabs and blood of febrile 
horses.  Intravenous inoculation of the blood of affected horses into susceptible animals 
may be required for virus isolation, all of which suggests that there is strain variation 
between EAV isolates (Clayton, 1987; Doll et al., 1957; McCollum and Bryans, 1973). 
   
3.2 Clinical signs of an EAV infection 
The clinical signs associated with an EAV infection vary widely from inapparent 
(or subclinical) to severe clinical infection. The signs displayed by EAV infected horses 
depend on a variety of factors including the age and physical condition of the horse(s), 
challenge dose and route of infection, strain of virus and environmental conditions 
(Timoney et al., 1987; Timoney and McCollum, 1993). The most common symptom of 
EVA is an upper respiratory tract infection but it can also result in abortion of pregnant 
mares, fulminant congenital infection in neonates, and persistent infection of the stallion 
with shedding of EAV in semen.   
Subclinical or mild infections are very common, especially in mares bred to 
persistently infected stallions. Epidemiological investigations of the 1984 outbreak of 
EVA in Kentucky revealed considerable variation in the incidence of clinical disease in 
naturally infected horses.  The ratio of clinical disease to inapparent infection in mares 
bred to a group of stallions with clinical EVA in this outbreak was 1.4:1.  In contrast, the 
corresponding ratio of a group of mares bred to a persistently infected carrier stallion was 
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1:6 (Timoney and McCollum, 1988).  During this epizootic 57% of affected farms had 
only 1 or 2 cases of EVA and just 14% of premises had 5 or more cases of the disease.  
The reason for this variation in the clinical severity of EVA is not clear. However, 
although there is only one serotype of EAV there is evidence of limited antigenic 
variation amongst EAV isolates (Murphy et al., 1988; Murphy et al., 1992) as well as 
variation in the pathogenicity of different isolates (McCollum and Timoney, 1996; 
Timoney and McCollum, 1988).  The clinical disease produced by different isolates can 
range from the severe and lethal experimental infections caused by the Bucyrus strain of 
the virus, to clinically inapparent infections transmitted by many long-term carrier 
stallions (MacLachlan et al., 1996; McCollum and Swerczek, 1978; Timoney et al., 1988; 
Timoney and McCollum, 1993). 
The clinical signs observed in natural cases of EVA vary considerably (Mumford, 
1985; Timoney and McCollum, 1987).  The incubation period of 3 to 14 days, usually 6 
to 8 days following venereal exposure, is followed by pyrexia of up to 41ºC that may 
persist for 2 to 9 days.  In addition to pyrexia, typical cases may have any combination of 
the following signs and symptoms: depression and anorexia; nasal and ocular discharge; 
conjunctivitis and rhinitis; leukopenia; periorbital and supraorbital edema; edema of the 
limbs, especially of the hind limbs; mid-ventral edema involving the scrotum and prepuce 
of the stallion and mammary glands of the mare; urticaria that may be localized to sides 
of the neck or face, or be generalized over most of the body; abortion of pregnant mares.  
Less frequently observed signs are icterus; photophobia; corneal opacity; coughing and 
dyspnea; abdominal pain and diarrhea; ataxia; petechiation of the nasal mucosa, 
conjunctiva and mucous membrane inside the upper lip; submaxillary and submandibular 
lymphadenopathy and adventitious edema in the intermandibular space, beneath the 
sternum or in the shoulder region (Burki and Gerber, 1966; Clayton, 1987; Collins et al., 
1987 Doll et al., 1957; Doll et al., 1957a; Gerber et al., 1978; Jaksch et al., 1973; Jones, 
1969; McCollum and Swercezk, 1978; Timoney, 1984; Timoney and McCollum, 1993).  
The most consistent clinical features of EVA are pyrexia and leukopenia. Regardless of 
the clinical severity, most naturally infected horses recover from EVA. In contrast, 
experimental inoculation with the virulent Bucyrus strain of EAV causes 60% mortality 
in adult horses (MacLachlan et al., 1996; Timoney and McCollum, 1993). 
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 Neonatal foals can develop severe fulminating interstitial pneumonia (Carman et 
al., 1988; Vaala et al., 1992). Foals up to few months of age can develop a rapidly 
progressive pneumo-enteric syndrome (Golnik et al., 1981) and deaths of foals following 
natural infections have been reported.   
Abortion in pregnant mares is often not foreshadowed by premonitory signs, and 
may occur late in the acute phase or early in the convalescent phase of the EAV infection 
(Bryans et al., 1957; Clayton, 1987; 1984; Doll et al., 1957; Timoney and McCollum, 
1993).  Abortions occur 10 to 33 days after EAV infection and are recorded between the 
160th and 300th day of pregnancy following natural or experimental infection (Cole et al., 
1986; Doll et al., 1957).  In natural outbreaks of EVA, abortion rates have varied from 
less than 10% to between 50 to 60% (Timoney and McCollum, 1993).  Infections with 
the strain of EAV that caused the 1984 Kentucky outbreak resulted in an abortion rate of 
71% (Cole et al., 1986). There are indications that different EAV isolates have different 
virulence characteristics and abortigenic potential.   
In the acute phase of EAV infection, stallions may undergo a period of temporary 
subfertility associated with reduced libido, decreased sperm motility, concentration, and 
percentage of morphologically normal sperm in ejaculates (Neu et al., 1992). In 
experimental infections, these changes persisted for up to 6 or 7 weeks after infection 
(Neu et al., 1988; Timoney et al., 1993).  These changes were believed to be due to 
increased testicular temperature rather than a specific pathologic effect of the virus. 
Transmission of EAV from persistently infected carrier stallions to mares at the time of 
breeding does not appear to cause any short- or long-term virus-related fertility problems 
(Timoney et al., 1993). Some 30 to 60% of mature infected stallions become carriers of 
the virus and shed virus in their reproductive tract for periods that range from several 
months to lifelong infection.   
  Apart from abortion in pregnant mares and fulminant respiratory disease in 
young foals, mortality does not occur in natural outbreaks of EAV (Timoney et al., 1993).   
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3.3 Pathogenesis and pathology of EAV infection of horses  
Information pertaining to the pathogenesis and pathology of EVA is mostly 
derived from experimental studies in horses inoculated with the virulent Bucyrus strain of 
EAV and by monitoring of natural outbreaks of EVA (Breese and McCollum, 1973; Cole 
et al., 1986; Crawford et al., 1973; Doll et al., 1957a; Estes et al., 1970; Fukunaga et al., 
1981; Fukunaga et al., 1982; Henson and Crawford, 1974; Jones et al., 1957; MacLachlan 
et al., 1996; McCollum et al., 1962; McCollum et al., 1971; McCollum, 1976; 
McCollum, 1981; McCollum and Timoney, 1996; Prickett et al., 1973). After nasal 
infection, the virus rapidly invades the respiratory endothelium and alveolar 
macrophages. By day two it is present in the bronchial lymph nodes (McCollum et al., 
1971). Replication occurs in the pulmonary lymph nodes, vascular endothelium and 
circulating monocytes. Virus then is disseminated throughout the body where it 
predominantly is localised in macrophages and dendritic cells in lymphoid tissues. The 
virus then further disseminates to a wide variety of tissues between 3 to 8 days after 
infection. Vascular injury is most severe at approximately 10 days, although it can persist 
for up to 14 days in the renal tubular epithelium. Infectious EAV is not detected after 28 
days except in the reproductive tract of persistently infected carrier stallions.  
The pathogenesis of abortion induced by EAV was controversial for a long time. 
Fetal infection and maternal factors, such as myometris and a reduced placental blood 
supply, originally were implicated (Coignoul and Cheville, 1984; Doll et al., 1957). A 
more recent study by MacLachlan et al. (1996), suggests that fetal stress, caused by in 
utero EAV infection, and subsequent activation of the fetal hypothalamic-pituitary axis 
more likely contribute to the pathogenesis of EAV induced abortion. 
The most common gross lesions in horses infected with the Bucyrus strain of 
EAV are severe panvasculitis that results from replication of the virus in vessels. 
Vascular injury leads to edema, congestion, and hemorrhage of the subcutaneous tissue, 
lymph nodes and viscera (Doll et al., 1957; Jones, 1969; MacLachlan et al., 1996). The 
body cavities may contain moderate to abundant amounts of yellowish clear fluid. 
Lymphadenomegaly, edema, hemorrhage can occur along the course of the colonic and 
ceceal vessels but are also evident throughout the body (Jones, 1969). The lungs, 
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especially those of infected neonates, are wet and increased in weight, with a prominent 
lobular pattern. The trachea may contain froth. 
Histopathological changes occur in various organs, but the blood vessels in all 
organs are the principal target. The vascular damage can vary from very mild lesions to 
severe endothelial and even transmural necrosis, leading to increased vascular 
permeability that results in the characteristic gross lesions. It is likely that the virus has a 
selective affinity for small arteries, specifically those of approximately 0.5 mm in 
diameter. These arteries are the smallest that have well developed muscular coats. 
Reports vary on the effects on arterioles, larger muscular and elastic arteries and veins 
(Del Piero et al., 1995; Estes et al., 1970; Jones, 1957). In general these vessels are less or 
not inflamed or necrotic. The lesions in the small arteries begin in the arterial media as 
necrosis of muscle cells, with loss of nuclei and replacement of cytoplasma with 
homogenous eosinophilic material (firbrinoid). Leukocytosis and edema of the adventitia 
are followed by edema of the media and infiltration with lymphocytes. The changes are 
often limited to small segments of affected arteries. Thrombosis can occur. The lungs 
show mild to severe interstitial pneumonia characterized by alveolar infiltration with 
macrophages and neutrophils, hyaline membrane formation, and fluid-filled alveoli. 
Follicle necrosis, edema and hemorrhage occur within the lymphoid tissues. EAV antigen 
is contained within the stromal dendritic cells and within the macrophages of lymph node 
sinuses and spleen. In adult horses lesions in the digestive system are most frequently 
observed in small intestine, large colon and cecum as edematous thickening of the 
submucosa along with engorgement of capillaries of submucosa and mucosa. The arterial 
lesions can range from simple necrosis and hyaline replacement of the media to 
thrombosis of the submucosal arteries with resultant infarction, mainly of the cecum and 
colon. Renal lesions occur in the terminal stages of infection and consist of tubular 
necrosis, lymphocytic interstitial nephritis and glomerular tuft disorganization.     
In pregnant mares experiencing abortion the uterine epithelial cells are swollen 
with accompanying edema and infiltration of neutrophils. The myometrium may contain 
necrotic myocytes, macrophages and swollen endothelial cells within affected areas. 
 Transplacental infection of the fetus occurs during EAV infection of pregnant 
mares, although histological lesions in aborted fetuses and the placenta are either 
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relatively subtle or non-specific (Balasuriya et al., 1997; MacLachlan et al., 1996). The 
changes are represented by mild perivascular lymphocytic and mild interstitial 
pneumonia. More severe lesions are rare and consist of vasculitis involving the 
allantochorion, brain, liver, spleen and lung.  
Foals that died a week after artificial inoculation showed more severe lesions. 
Infarction of the intestine was found more often than in the lung (Johnson et al., 1991; 
Jones et al., 1957). 
Lesions in the male reproduction tract have been studied in experimentally 
infected prepubertal and peripubertal colts (Holyoak et al., 1993). During the acute phase 
of the infection, 7-14 days post- infection, acute necrotizing vasculitis involving the 
testis, epididymides, vas deferens, ampulae, prostate, vesicular glands and bulbourethral 
glands was present. Multifocal lympho-plasmocytic infiltrate in the ampulae and 
parachyma of the reproductive tract occurred in the chronic phase of infection.  
    
 
3.4 Equine immune response to an infection with EAV 
Immunity is prolonged after natural or experimental infection of horses with EAV 
(Doll et al., 1957; Doll et al., 1968; Fukunaga et al., 1990; Gerber et al., 1978; Hullinger 
et al., 1998; McCollum, 1986).  Immune horses were protected from clinical EVA when 
challenged with the virulent strain of EAV, and the humoral immune response was 
characterized by the development of both complement-fixing and neutralizing antibodies 
to EAV (Fukunaga and McCollum, 1977; McCollum, 1970) that are detected 1 to 2 
weeks after infection. The complement-fixing antibodies peaked at 2 to 3 weeks and 
steadily declined to disappear by 8 months post infection, whereas neutralizing antibodies 
peaked between 2 to 4 months and persisted for 3 years or more. The serum 
neutralization titers can increase with advancing age, likely as a consequence of 
reinfection (Burki et al., 1992). Mares with anti-EAV antibodies prior to being bred to 
carrier stallions also had an obvious anamnestic humoral immune response.    
Colostrum from immune mares contains EAV- neutralizing antibodies that protect 
foals against clinical EVA (Hullinger et al., 1998; McCollum, 1976). The neutralizing 
antibodies appear in the serum a few hours after feeding of colostrum, peak at 1 week of 
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age, and gradually decline to disappear between 2nd and 6th month of age. Passive 
immunization studies have shown that the transfer of maternal antibodies is highly 
effective in preventing EVA, even following intranasal inoculation of highly virulent 
EAV strains (McCollum, 1976). 
The serologic responses of EAV infected horses to the four known EAV structural 
proteins have recently been characterized (Hedges et al., 1998; Kondo et al., 1998). 
Differences in humoral immune responses of 34 horse sera were apparent in Western 
immunoblotting studies utilizing the M, N, GL and GS proteins expressed by recombinant 
baculoviruses and in purified virions (MacLachlan et al., 1996). The data show that the 
immune response of individual horses is dependent on the infecting EAV strain and 
interval after infection. The conserved M protein was most consistently recognized by 
sera from horses naturally and experimentally infected with EAV (MacLachlan et al., 
1996).  Another Western immunoblotting assay that utilized N and M proteins also 
identified the M protein as a major target of the equine humoral immune response 
(Kheyar et al., 1997). Recent immunisation studies using alphavirus-based expression 
vectors have shown that the co-expression of GL and M proteins is required for the 
induction of neutralizing antibodies in mice (Balasuriya et al., 2000). This result was then 
confirmed by a study, in which only horses that received a vector that co-expresses both 
the GL and M proteins were protected against challenge with a virulent strain of EAV 
(Balasuriya et al., 2001).  
The response of horses to the non-structural proteins of EAV has not been 
determined yet. Recent testing of different equine sera by immonoprecipitation assay 
suggests that equine antisera recognize both the nsp1 and 2 proteins of EAV (Snijder, 
unpublished data).  
 
3.5 Epidemiology   
In 1953 a severe outbreak of EVA occurred on a standardbred stud farm in 
Bucyrus, Ohio, that ultimately resulted in the identification of EVA as a distinct virus 
disease of horses (Doll et al., 1957; Doll et al., 1957a). Since the original discovery 
several outbreaks have been reported from Germany (Burki and Gerber, 1966; Herbst and 
Danner, 1985; Kaaden et al., 1990; Liebermann, 1988; Nowotny and Burki, 1992; Pesch 
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et al., 1998; Schneller et al., 1996), Switzerland (Burki, 1970; Burki and Gerber, 1966; 
Golnik et al., 1981; Weiss et al., 1994), Austria (Jaksch et al., 1973; Kolbl et al., 1991; 
Nowotny, 1992; Nowotny and Burki, 1992), Poland (Golnik et al., 1981; Golnik et al., 
1986), Italy (Autorino et al., 1992; Cancellotti and Renzi, 1992; Cecarelli et al., 1996), 
the United Kingdom (Anonymous, 1988; Anonymous, 1993; Camm and Thursby-
Pelham, 1993; Higgins, 1993; Higgins, 1993a; Newton et al., 1999; Wood et al., 1995), 
Spain (Monreal et al., 1995), the Netherlands (van Gorkom et al., 1994), Canada 
(Clayton, 1987; Klavano, 1987) and the United States (Dwyer et al., 1993; McCollum et 
al., 1962; Mumford, 1985; Timoney, 1984; Timoney and McCollum, 1993). The first 
recorded outbreak in the United Kingdom followed the importation of an Anglo-Arab 
stallion from Poland (Higgins, 1993). The three major outbreaks in the United States 
were reported on a racetrack in Kentucky in 1977 (McCollum and Swerczek, 1978), in 
Thoroughbred horses during breeding season in 1984 in central Kentucky (McCollum 
and Timoney, 1996; Timoney et al., 1988) and on the Arlington racetrack in Chicago in 
1993 (Dwyer et al., 1993). This last outbreak also affected horses at Churchill Downs, 
Prairie Meadows and Ak-Sar-Ben (McCollum et al., 1994). Today EAV is distributed 
throughout the world. Serological surveys have shown that EAV infection occurs in 
North America (Chirnside, 1992; Lang and Mitchell, 1984; McCue et al., 1991), Europe 
(Akashi et al., 1976; Akashi et al., 1975; Burki et al., 1992; de Boer et al., 1979; de Boer 
et al., 1978), South America (Nosetto et al., 1984), Australia (Anonymous, 1988; 
Huntington et al., 1990; McKenzie, 1988; McKenzie, 1990; McKenzie, 1996), Africa 
(Moraillon and Moraillon, 1978; Moraillon et al., 1978; Paweska, 1994; Paweska and 
Barnard, 1993) and Asia (Akashi et al., 1975; de Vries, 1994). Infection is especially 
prevalent in standardbred horses (McCollum and Bryans, 1973; McCue et al., 1991; 
Timoney et al., 1988). Serological surveillance in South Africa has shown that EAV 
infection also occurs in donkeys (Paweska, 1994; Paweska et al., 1997).  
EAV can be spread both vertically (congenital infection of foals) and horizontally 
(respiratory and venereal transmission). It has been reported that exposure of pregnant 
mares in very late gestation to EAV can lead to transplacental transmission of the virus 
and congenital infection of the fetus (Balasuriya et al., 1999; Balasuriya et al., 1998; 
Vaala et al., 1992).  EAV is not teratogenic, but congenitally infected foals develop a 
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rapidly progressive, fulminating interstitial pneumonia and/or fibronecrotic enteritis 
(Carman et al., 1988; Golnik et al., 1981; Lopez et al., 1994). 
   Horizontal transmission is of greater significance to the international spread of 
EAV than vertical transmission (Burki, 1965; Burki et al., 1992; Cole et al., 1986; Doll et 
et al., 1957; McCollum et al., 1961; Timoney et al., 1987a; Timoney et al., 1992; 
Timoney and McCollum, 1993). Horizontal transmission via the respiratory route occurs 
in acute infections following aerosolization of respiratory tract secretions from acutely 
infected horses. This has been demonstrated during the course of natural and 
experimental infections (Doll et al., 1957; McCollum et al., 1971; McCollum and 
Swerczek, 1978). Aborted materials such as fetuses, placenta and amniotic fluid and 
materials from infected animals, such as urine, vaginal and lacrimal secretions, feces and 
blood can also contribute to horizontal transmission (Cole et al., 1986; Fukunaga et al., 
1981; McCollum and Timoney, 1996; Neu et al., 1988; Timoney and McCollum, 1993).  
Masturbates of acutely and/or chronically infected stallions have been discussed as 
another potential source for aerosol transmission (Burki et al., 1992). Considering that 
direct and close contact is necessary for aerosol transmission of EAV (Collins et al., 
1987; Timoney and McCollum, 1988), the most important and primary route of 
dissemination of EAV during outbreaks is the aerosolization of infectious particles 
(McCollum et al., 1971; McCollum et al., 1971). The virus is shed in high concentrations 
in respiratory secretions for up to 7 or 14 days during acute infection (McCollum et al., 
1971). However it has been demonstrated that direct and close contact is necessary for 
aerosol transmission of EAV (Collins et al., 1987; Timoney and McCollum, 1987). The 
second important mode of transmission is the venereal transmission, from acutely or 
chronically infected stallions that shed the virus in their semen (Kaaden et al., 1990; 
Timoney, 1986; Timoney et al., 1993; Timoney and McCollum, 1987). This was first 
demonstrated after the 1984 epidemic in Kentucky (Kaaden et al., 1990; Timoney et al., 
1987; Timoney and McCollum, 1993; Timoney et al., 1987a). The venereal transmission 
by long-term carrier stallions is important for perpetuation and maintenance of the virus 
in equine populations throughout the world.  They appear to shed virus solely by the 
venereal route. Some 85 to 100% of seronegative mares bred to long-term carrier 
stallion’s seroconvert to EAV within 28 days after breeding. Mares are readily infected 
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following artificial insemination with semen from a long-term carrier stallion (McCollum 
et al., 1988). 
Transmission also may occur through indirect contact (e.g. personnel, vehicles, 
twitches, apparels and shanks) and congenital infected foals (Collins et al., 1987; 
Timoney et al., 1988). Other potential modes of transmission of EAV appear to be teaser 
stallions and nurse mares (Timoney et al., 1993). EAV has been experimentally 
transmitted by the intravenous, subcutaneous, intranasal and intratracheal inoculation of 
lung or spleen suspensions from acutely infected horses (Doll et al., 1957; McCollum et 
al., 1971; Timoney and McCollum, 1993). EAV also has been successfully transmitted by 
inoculating tissue culture supernatants from infected cell lines (Fukunaga et al., 1982; 
MacLachlan et al., 1996).  Burki et al. (1972) failed to propagate EAV in Aedine and 
Anopheline mosquitoes, and concluded that arthropod transmission is not involved in 
virus dissemination.   
Until the 1984 epizootic in Kentucky there was very little information available 
regarding the carrier state of EAV. However it was noted in the nineteenth century that 
healthy stallions transmitted epizootic cellulitis-pink-eye and influenza to mares at the 
time of breeding, which very likely was EVA (Clark, 1892; Plataeu and Hacquet, 1888). 
It was postulated, based on clinical observation and transmission studies, that the 
causative agent of EVA is shed in the semen of certain convalescence stallions (Clark, 
1892; Plataeu et al., 1888). In 1913 Bergmann et al. reported that a persistently infected 
stallion continued to transmit the disease to mares for almost seven years.  He also 
reproduced the disease by inoculating susceptible horses with seminal fluid from a 
persistently infected stallion. Schofield (Bishop, 1989) described in 1937 two outbreaks 
of “equine influenza” that were attributed to carrier stallions. Investigations of the 1984 
EVA outbreak on Thoroughbred farms in Kentucky reconfirmed the importance of the 
carrier stallion in the dissemination and perpetuation EAV infection (Timoney et al., 
1987; Timoney and McCollum, 1992).  Timoney et al. (1986) confirmed the chronic 
carrier state in Thoroughbred stallions naturally infected with EAV using test mating 
and/or isolation of virus from semen. Both short term and long term convalescent carriers 
were identified (Timoney et al., 1986; Timoney and McCollum, 1992). One of the 
possible factors that may influence the carrier state is the period of sexual rest given to 
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stallions following exposure to EAV. An insufficient period of sexual rest following 
exposure to the virus may predispose to establishment of persistent infection. Extensive 
epidemiological studies involving both, Standardbred and Thoroughbred horses, failed to 
demonstrate any breed predilection for establishment of persistent infections, with 30 to 
35% of naturally infected stallions becoming long-term carriers (Timoney et al., 1992).   
Persistently infected stallions can be divided into three groups based on their 
duration of virus shedding in semen (Timoney et al., 1987; Timoney et al., 1992). The 
short-term or convalescent carrier state lasts only a few weeks after clinical recovery.  
The intermediate carrier state lasts for 3 to 7 months in both naturally and experimentally 
infected animals (Timoney et al., 1992).  The long-term or chronic carrier state can last 
for several years.  Persistently infected long-term carrier stallions spontaneously may 
cease virus shedding after intervals of 1 to 10 years, with no apparent later reversion to a 
shedding state. The mechanism responsible for this spontaneous clearance of EAV from 
persistently infected stallions has not been discovered yet, but studies have shown that 
persistence of EAV in stallion is testosterone-dependent (Little et al., 1992; McCollum et 
al., 1994). When persistently infected stallions were castrated and treated with 
testosterone they continued to shed the virus in semen, whereas saline treated animals 
ceased shedding virus. The immunosuppressive effects of high levels of circulating 
testosterone also might allow the virus to persist in the male reproductive tract.   
Studies of the persistence of EAV in prepubertal and peripubertal colts (Holyoak 
et al., 1993a) indicated that EAV could replicate in the male reproductive tract of a 
significant proportion of colts for a variable period of time after clinical recovery (up to 
six months). The absence of circulating concentrations of testosterone, equivalent to 
those found in sexually mature stallions, prevents long-term persistent infection with 
EAV and colts exposed to the virus before the onset of puberty did not become 
persistently infected. There is no evidence that carrier stallions are or can become 
intermittent shedders of the virus or have latent infection. The virus is contained within 
the sperm-rich fraction and not within the pre-ejaculatory fluid of semen, and there is 
little variation in virus titers contained in sequential ejaculates from the same stallion. 
All carrier stallions have moderate to high titers of serum neutralizing antibody to 
EAV and shed the virus constantly in the semen but not in urine or in respiratory 
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secretions (Timoney et al., 1987). The ability of the virus to persist in the face of 
moderate to high titers of neutralizing antibodies clearly indicates that humoral immunity 
does not prevent viral replication within the male reproductive tract. EAV has not been 
isolated from the buffy coat of persistently infected stallions.  EAV is localized in 
different parts of the male reproductive tract and highest titers of virus consistently have 
been demonstrated in the ampulla of the vas deference and the bulbourethral glands with 
> 105 PFU per gram of tissue (Fukanaga et al., 1992; Neu et al., 1988).  
There is no evidence to indicate that mares or congenitally infected foals become 
persistently infected following infection with EAV (Timoney et al., 1988; Timoney and 
McCollum, 1993).  EAV was not isolated from the reproductive tract of seropositive 
mares one month after infection (McCollum and Timoney, 1996) and the consistent 
failure to transmit the virus to susceptible horses during mating or at pasture has lead to 
the conclusion that the carrier state does not exist in the mare (Burki et al., 1992; 
Chirnside, 1992). 
 
3.6 Diagnostics 
The clinical signs of EVA vary widely and can occur in different combinations. A 
number of infectious and non-infectious diseases of horses show similar clinical signs, 
and therefore a presumptive diagnosis cannot be based only on the presence of 
characteristic signs (McCollum et al., 1970; Timoney and McCollum,1993). The list of 
differential diagnosis of EVA includes other viral respiratory tract infections of horses, 
such as equine herpesvirus 1 and 4, equine influenza, equine rhinovirus, equine 
adenovirus, equine infectious anemia and African horse sickness. Non-viral infections 
include leptospirosis, purpura hemorrhagica, urticaria and toxicosis due to hoary alyssum 
(Berteroa incana). The characteristic lesions of arteritis may help to differentiate EVA 
from some of the other diseases, but they are not pathognomic for EVA.  After 
performing an immunoperoxidase histochemistry staining of skin biopsies from two EAV 
infected horses, Del Piero (2000) suggested that this test may be used as a supporting test 
for the clinical diagnosis, especially when a cutaneous macropapular rash is evident. In 
cases of abortion the primary differential diagnosis should include herpesvirus 1 and 
rarely herpesvirus 4. Herpesvirus-infected fetuses are expelled without any premonitory 
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signs; they are mostly fresh and have characteristic gross lesions. On the contrary fetuses 
aborted after EAV infections are often partly autolysed and lack pathognomic lesions. 
  The currently used, officially recommended, method for detection of EAV in 
semen and tissue samples is virus isolation in susceptible cell culture, although modern 
molecular methods are also available today (Belak et al., 1994; Gilbert et al., 1997; 
Herbst and Danner, 1985; Herbst et al., 1996; Klug and Sieme, 1999; Starik, 1999; St-
Laurent et al., 1994).  
The isolation and propagation of EAV from equine tissue was originally carried 
out on primary equine kidney cell cultures (McCollum et al., 1961), whereas the RK-13 
continuous cell line is now more commonly used. Any viruses isolated in RK-13 cells are 
confirmed to be EAV by immunohistochemical staining with EAV-specific antisera 
(immunofluorescence, immunoperoxidase) or microneutralization assay with EAV 
specific antibodies. Virulent EAV strains, such as the Bucyrus strain, are not difficult to 
isolate, whereas other strains can be problematic. During the Kentucky outbreak in 1977 
(McCollum 1981), viruses could not be isolated from nasal swabs or buffy coat of febrile 
horses. The same observation was made during the outbreak in Switzerland (Gerber et al., 
1978). In addition there are reports that viruses that cause subclinical infections in 
Standardbred nurseries (McCollum ad Bryans, 1973) and the modified Bucyrus strain of 
EAV (vaccine) may be difficult to recover from affected horses (McCollum, 1969; 
McCollum et al., 1970).  
Nasopharyngeal swabs, conjunctival swabs and citrated, heparinized EDTA blood 
samples for the separation of buffy coat are the usual samples for virus isolation from live 
horses. Semen is used for the detection of persistently infected stallions, with virus being 
detected by either isolation or RT-PCR assay. The specimens for the virus isolation 
should be collected as soon as possible after the onset of clinical signs of EVA. The 
nasopharyngeal and conjunctival swabs should be immediately placed in transport 
medium (any cell culture medium or balanced salt solution containing 2 to 5% antibody 
free serum) and either refrigerated or, preferably, frozen at –200C or lower (Timoney et 
al., 1988). For serological diagnosis acute and convalescent sera (paired serum samples) 
at a 21 to 28 day interval should be collected. In the case of abortion the placenta, fetal 
fluid, lung, spleen and lymphoid tissue should be collected for virus isolation and antigen 
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demonstration. In young foals that show signs of pneumonia and enteritis, a wide variety 
of tissues should be collected. 
The continued movement of persistently infected stallions and infected semen 
emphasizes the need for a rapid, sensitive and specific test to detect EAV. Virus isolation 
in cell culture or test breeding of stallions to mares are both time consuming and 
expensive, thus reverse transcription-polymerase chain reaction (RT-PCR) based 
methods have been developed although they are not yet in widespread routine use (Belak 
et al., 1994; Gilbert et al., 1997; Ramina et al., 1999; Sekiguchi et al., 1995; Starik, 1998; 
St-Laurent et al., 1994). Detection of EAV by real-time PCR has been described recently 
by Balasuriya et al. (2002). TaqMan ® RT-PCR minimizes the risk of cross 
determination and provides an accurate and quantitative test for detection of EAV in 
clinical specimens.    
Serological tests to determine previous exposure of horses to EAV include the 
serum neutralization (SN) test, complement fixation (CF) test and enzyme-linked 
immunosorbent assay (ELISA; Senne et al., 1985; Fukunaga and McCollum, 1977; 
Fukunaga et al., 1994; Fukunaga, 1994) The complement fixation test is simple and 
rapid, but it is rather insensitive and can only detect horses that were recently infected.  
The current standard test for the serological diagnosis of EAV infection is the SN 
test (Senne et al., 1985).  Although highly sensitive and specific, there are several 
inherent disadvantages to this test.  The assay is expensive and time consuming to 
perform, and it requires the growth and maintenance of cell cultures as well as infectious 
virus.  In addition, results tend to vary between laboratories when the reagents are not 
standardized. Addition of 10% guinea pig complement to the assay increases 
reproducibility and sensitivity (Fukunaga et al., 1993; Hyllseth and Pettersson, 1970; 
Maess, 1971; Radwan and Crawford, 1974; Radwan and Burger, 1973).  The SN assay 
putatively detects antibodies to the variable GL protein, which includes the known 
neutralization determinants of EAV (Balasuriya et al., 1993; Balasuriya et al., 1995; 
Balasuriya et al., 1995a; Chirnside et al., 1995; Deregt et al., 1994). 
Several different EAV-specific ELISAs have recently been developed in an effort 
to develop one that is sufficiently specific and sensitive to replace the SN test. These 
ELISAs include a variety of different antigen preparations, all based on EAV proteins. 
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Several ELISAs that incorporate whole virus or recombinant N, M and GL 
proteins have been described for the serological diagnosis of EAV infection (Chirnside et 
al., 1995; Chirnside et al., 1995a; Chirnside et al., 1995b; Kondo et al., 1998a, Starik et 
al., 2001). Iniguez et al. (1998) used a random peptide library displayed on phage as 
antigen in an ELISA. Assays that utilized whole virus antigen preparations produced an 
unacceptable number of apparent false positive results as horses vaccinated with tissue 
culture-derived vaccines can develop antibodies to cell culture proteins remaining in the 
EAV whole virus antigen preparation (Weiland et al., 2000). ELISA and Western 
immunoblotting assays that utilize the N, M and GL proteins of EAV, and peptides 
expressed as bacterial fusion proteins, all provide potentially sensitive and specific 
antigens for ELISAs for the serological diagnosis of EAV infection, however, the 
bacterial fusion partner may contribute significantly to background absorbance, 
potentially compromising specificity (Chirnside et al., 1995; Chirnside et al., 1995a; 
Chirnside et al., 1995b; Kheyar et al., 1997). An ELISA assay that incorporated 
individual baculovirus expressed M, N and GL proteins confirmed that the M protein is 
most consistently recognized by convalescent equine sera (Hedges et al., 1998).  The 
responses of individual animals varied and ELISAs that utilized individual EAV 
structural proteins were not consistently reliable in the detection of sera that contained 
neutralizing antibodies to EAV. An ELISA based on a cocktail of all three EAV 
structural proteins, however, was used successfully to detect antibodies in most equine 
sera that were positive in the standard serum neutralization assay following natural or 
experimental EAV infection (100% specificity, 92.3% sensitivity).  All sera from carrier 
stallions and annually vaccinated horses evaluated in this study had obvious reactivity 
with the N protein, whereas seropositive non-carrier stallions, mares, and geldings did not 
consistently respond to the N protein.  This finding may be useful in screening stallions 
for persistent EAV infection, however it does not reliably distinguish persistently infected 
stallions from vaccinated stallions. 
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3.7 Prevention and control  
The prevention and the control of EVA outbreaks are important because there is 
no treatment for infected animals, only supportive care.  
For quarantine management it is important to recognize that mares who become 
infected shed the virus from the respiratory tract only for 14 days and from the vaginal 
tract for approximately eight days. Thus, mares isolated for three weeks after exposure 
pose no significant risk for the spread of disease. There is no evidence that foals infected 
in uteri either develop malformations or become carriers of EAV. 
The approach to prevention and control of EVA has been dramatically changed 
since the 1984 outbreak in Kentucky, and several management procedures have been 
proposed (Anonymous, 1993; Fukunaga, 1994; Glaser et al., 1996; Lasalle, 1969; 
Mumford, 1985; Timoney et al., 1988). These programs are primarily directed at 
controlling the spread of EAV amongst breeding Thoroughbred populations through 
carrier stallions. Sensitive breeding management based on the different status of 
individual stallions and mares appear to effectively control the spread of the virus. Only 
seronegative stallions should be bred to negative mares. Stallions can be infected at any 
time after puberty and are then likely to become carriers. Therefore, all breeding stallions 
should be closely monitored and the semen of carrier stallions should be regularly tested 
for the presence of virus. Stallions can reclaim their virus free status if minimums of two 
semen samples, collected with an interval of at least one week, are negative for the virus 
(Klug, 1999). In controversial cases stallions can be test bred to two seronegative mares, 
following the Codes of Practice of the Horse-Race Betting Levy Board.  A persistently 
infected stallion can be used for breeding, but should only be bred to seropositive mares 
or mares that have been vaccinated at least six weeks prior to the breeding.  
The most effective method of prevention is vaccination (Anonymous, 1993b; 
Cook et al., 1989; Fukunaga et al., 1984; Fukunaga et al., 1990; Fukunaga et al., 1997; 
Harry and McCollum, 1981; McCollum, 1996; McCollum, 1986; McKinnon et al., 1986). 
Currently two vaccines are available for the control of EAV infection, a modified live 
virus (MLV) vaccine (ARVAC TM, Fort Dodge Laboratory) and a killed whole virus 
adjuvanted vaccine (Artevac, Ford Dodge Laboratories, Sligo, Ireland). The MLV was 
obtained by passing the Bucyrus strain of EAV 131 times in horse kidney cells, 111 times 
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in rabbit kidney cells and 24 times in equine dermal cells (Doll et al., 1968; McCollum, 
1970; McCollum et al., 1986). The vaccine has been used in the United States of America 
since 1985, but it is not licensed worldwide. The ARVAC TM vaccine is freeze-dried 
(lyophilized) and highly stable at -20°C for at least a year, relatively stable at 4°C and has 
a short life at 37°C. The vaccine is delivered with its own dilution solution and is 
delivered intramuscularly (dosage 1ml per animal). Neither persistent infection nor 
clinical signs occur after vaccination and protective immunity lasts for approximately a 
year. Although vaccination does not protect vaccinated horses from reinfection, the 
vaccine virus was isolated from an aborted fetus (Cole et al., 1986), thus it is only 
recommended for use in stallions and non-pregnant mares. Its use is especially 
discouraged in pregnant mares in the last two months of gestation (Hyllseth et al., 1970; 
Timoney et al., 1988a; Timoney and McCollum, 1993).  The Artevac vaccine was 
licensed in the United Kingdom in 1993 under the Animal Test Certificate and has been 
widely used since then. May 2002 the vaccine was licensed in Germany, and Fort Dodge 
released the product to the market in autum 2003. 
 Many countries prohibit widespread use of the currently available vaccines 
because the vaccines do not permit serological discrimination between naturally infected 
and vaccinated animals. Thus, vaccinated animals may suffer movement restrictions due 
to their serological status. Considerable effort has recently been expended to develop a 
subunit vaccine, which offers considerable theoretical advantage, including lack of 
replication and the ability to distinguish vaccinated and naturally infected horses 
(Anonymous, 1993; Balasuriya et al., 2001; Castillo-Olivares et al., 2001; Fukunaga et 
al., 1992; Fukunaga et al., 1997; Giese at al., 2002; Tobiasch et al., 2001).  Boehringer 
Ingelheim Animal Health shows further approaches to a vaccine in a recent study. Using 
a DNA vaccine containing EAV ORF 2, 5 and 7 in combination with equine interleukin 
2, all horses developed a high titer of neutralizing antibodies, which where still detectable 
after 12 months (Giese et al., 2002). 
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4. Materials 
 
All materials and chemicals used for this study are standard items and have been acquired 
from either Sigma-Aldrich, Inc. or Fisher Scientific, International Inc., unless noted 
otherwise. 
 
4.1 Cell lines 
BHK-21 Baby Hamster Kidney-21; (ATCC #CCL-10)  
P3x     P3x63Ag.8.653 cells (ATCC #CRL-1850); 
RK13     Rabbit Kidney-13 (ATCC #CCL-37); 
 
4.2 Media and media supplement for cell culture 
- Carboxymethyl Cellulose Sodium Salt (CMC) Solution  
Dilute 3 g CMC in 70 ml dH2O, stir until 90% are resolved. Autoclave, add 330 ml of 
cell line specific growth media before use, stir overnight at 4°C. 
- Hypoxanthine-Aminopterin-Thymidine (HAT) medium 
RPMI-1640 (Gibco)       800 ml   
HAT media supplement       1 vial   
Fetal bovine serum (FBS; HyClone)     100 ml  
Origen Hybridoma cloning factor      100 ml   
Non–essential amino acids (100x; Gibco)    10 ml  
Sodium pyruvate (100x; Gibco)     10 ml  
Gentamycin (50 mg/ml; BioWhittacker)    1.0 ml 
- Hypoxanthine-Thymidine (HT) medium 
RPMI-1640        800 ml   
HT media supplement       1 vial   
FBS         100 ml   
Origen Hybridoma cloning factor     100 ml   
Non–essential amino acids (100x)     10 ml  
Sodium Pyruvate (100x)      10 ml  
Gentamycin (50 mg/ml)      1.0 ml 
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- Freezing medium 
FBS         50% 
Cell line specific growth media     40% 
Dimethyl Sulfoxide, sterile filtered (DMSO)    10% 
- Nutrient media for BHK-21  
Minimum essential media  (MEM; Gibco)    400 ml   
Tryptose phosphate broth (Difco)     50 ml   
FBS          50 ml 
Penicillin and Streptomycin (100x; BioWhittaker)   5 ml 
- Nutrient RPMI Media for P3X63Ag8.653  
RPMI-1640        450 ml   
FBS          50 ml   
Non-essential amino acids (100x)     5 ml 
Sodium Pyruvate (100x)      5 ml 
- Nutrient media for RK-13 
MEM         400 ml   
Calf serum (CS; HyClone)      50 ml   
Penicillin and Streptomycin (100x)     5 ml   
Polyethylene glycol solution 40% 
PEG 1450 (50x; ATCC)      1 vial 
RPMI-1640        3 ml 
- STV-solution 
Sterile water        400 ml 
PBS (20x, sterile)        21 ml 
Trypsin-Ethylin-diamin-tetracidic-acid (EDTA; Gibco)  47 ml 
Phenol red (Sigma)         1 ml 
 
4.3 Buffers and solutions 
- Acetic acid 3% solution 
Acetic acid, glacial        3 ml   
dH2O         100 ml 
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- Citrate acid solution` 
0.1M Citrate acid        21.01 g 
dH2O, sterile filtered       1000 ml 
Adjust the pH to 4.5 
- ELISA blocking buffer 
3% Non-fat dry milk powder (Safeway brand)   3 g 
Elisa wash buffer        100 ml    
Stir for 1h and afterwards centrifuge at 3000 rpm (max) for 30 min. Decant the 
supernatant into a clean beaker before use. 
- ELISA coating buffer 
3.5% Triton-X-100 Stock       3.5 ml 
PBS; sterile filtered       100 ml 
To make working solution 
0.0035% Triton-X-100      1 ml of stock  
PBS; sterile filtered       1000 ml 
- ELISA HRP substrate solution  
0.1 M Citrate acid solution, pH 4.5     10 ml 
Hydrogen Peroxidase (30% soln.)     3.3 µl 
O-Phenylenediamine Dihydrochloride (OPD)   10 mg 
- ELISA stopping solution 
1% Sodium Dodecyl Sulfate (SDS)      1 ml 
dH20         100 ml 
- ELISA Wash buffer 
0.05 % Triton-X-100       1 ml 
PBS          2 l 
- IFA Antibody dilution solution  
FBS         5 ml 
PBS         95 ml 
- IFA Fixative 
3 % Paraformaldehyde       3 ml 
PBS         97 ml 
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- IFA Permibalization solution 
Trition-X-100         1 ml 
PBS         99 ml 
- IFA wash solution 
10mM Glycine        0.76 g 
PBS Qs to        1000 ml 
- Phosphate Buffered Saline (PBS) 
NaCl         8.0 g   
KCl         0.2 g   
Na2HPO4        1.15 g   
KH2PO4        0.2 g  
H2O fill up to        1000 ml 
- Solubilization buffer 
20mM Tris HCl       3.152 g/l dH2O 
20mM Tris Base       2.43 g/l dH2O 
-> Mix both until a pH of 7.6 is reached now add: 
1% Igepal CA-630 (NP-40)      10 ml/l 
0.5% Sodium deoxycholate       5 g/l 
0.1% Sodium dodecylsulfate (SDS)     1 g/l 
Phenylmethyl-Sulfonyl Flouride (PMSF)    17 µg/ml  
(1ul of 0.1M PMSF/ml,  
0.1M Stock solution [0.1742 g in 10 ml of 2-propanol]) 
Aprotinin (Roche)       1 µg/ml   
Leupepton (Roche)       1 µg/ml 
Pepstatin (Roche)       1µg/ml 
- Trypan blue solution 
0.2% Trypan blue        0.2 ml 
Sterile filtered PBS       100 ml 
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- Western immunoblot washing buffer (TBS-T), pH 7.6 
20mM Tris Base       2.43 g   
137mM NaCl        7.73 g  
HCl (6N)        3.8 ml   
0.05 % Tween 20       0.5 ml   
dH2O qs to        1000 ml 
- Western immunoblot antibody dilution buffer (ADB) 
Nonfat dry milk       10 g    
NaN3         0.1 g   
NaCl         9 g   
Na2H2PO4 dibasic       4.5 g   
NaH2PO4 monobasic       0.5 g   
PBS         100 ml  
- Western immunoblot protein dilution buffer (ADB):  
Laemelin sample buffer (BioRad)     2 ml 
50mM Dithiothreitol (DTT)      16 mg 
- Western immunoblot blocking buffer 
5% nonfat dry milk (Safeway)     5 g 
TBS-T         100 ml 
- Western immunoblot conjugate dilution buffer (CDB)  
1% nonfat dry milk       1 g   
0.05% Tween-20        0.5 ml  
PBS         1000 ml 
- Western immunoblot SDS-PAGE running buffer 
Glycine        58 g 
Tris base        12 g 
SDS         4 g 
dH2O qs to        400 ml 
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- Western immunoblot transfer buffer (proteins <80.000MW) 
25mM Tris base       3.08 g 
190mM Glycine        15.24 g  
20% Methanol        20 ml 
dH2O qs to        1000 ml 
 
4.4 Enzymes and other proteins 
Biotinylated Protein Marker Detection Pack  Cell Signaling Technology  
Guinea pig complement C300   Gibco 
M88       Balasuriya et al. (unpublished data) 
(NH2-Met-Pro-Arg-Leu-Arg-Ser-Ile-Phe-   
Asn-His-Arg-Gln-Leu-COOH) 
M148       deVries et al., 1992 
(NH2- Tyr-Ala-Gly-Arg-Leu-Phe-Ser-Lys- 
Arg-Thr-Ala-Ala-Thr-Ala-Tyr-Lys-Leu- 
Glu-COOH       
nsp1, 2 and 4      recombinant fusion proteins;   
       Snijder (unpublished data) 
EAV.030H      van Dinten et al., 1997 
 
4.5 Antibodies and antisera 
12a4a11b3f2 IgG    MAb anti-NSP1; Wagner et al., 2003 
1H7, 1H9, 2B3, 3F4, 5E8, 5F3, 5G11,  MAbs anti-GL;  
6A2, 6D10, 7C5, 7E5, 7D4, 8D4,   Balasuriya et al., 1995 
9F2, 10B4, 10H4.F9, 10F11      
MAb anti-N      3E2, Rabbit #11428, ascites; 
MacLachlan et al., 1996 
polyclonal anti-M     Rabbit #887 serum; 
MacLachlan et al., 1998 
polyclonal anti-nsp1     Rabbit anti-nsp1serum; 
Snijder et al., 1994 
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O16 IgG       MAb anti-BTV; Heidner et al., 1990  
Biotinylated-Goat Anti-Mouse IgG   Zymed Laboratories Inc.; SF  
Biotinylated-Goat Anti-Rabbit IgG (H+L)  Zymed Laboratories Inc.; SF  
HRP-Streptavidin conjugate    Zymed Laboratories Inc.; SF 
FITC Conjugates-Goat Anti-Mouse IgG  Sigma, MO 
FITC Conjugates-Goat Anti-Rabbit IgG  Sigma, MO 
 
4.6 Equine sera 
Fifty horse sera that were confirmed to be seronegative to EAV by serum 
neutralization (SN) test and 50 SN-positive sera were evaluated. The latter included 11 
sera from experimentally EAV-infected horses, 19 sera from naturally EAV-infected 
horses, and 20 from horses vaccinated with the modified live virus (MLV) vaccine 
(ARVAC, Fort Dodge Laboratories, Ames, IA). Many of these sera had been previously 
evaluated by Western immunoblotting assay and direct ELISA using various recombinant 
EAV proteins as antigen (Hedges et al., 1998; McLachlan et al., 1998), and the SN titers 
of all sera also had been determined as previously described (Senne et al., 1985). The SN 
titers of the various equine sera ranged from <4 to 5125 (reported as the reciprocal of the 
highest dilution providing 50% protection of the EAV-infected cell monolayer). 
 
4.7 Chemicals 
Acrylamide/Bis, 30%/0.8%     Bio Rad 
Ammonium Persulfate (APS)    Bio Rad 
DAKO Fluorescent Mounting Medium   DAKO 
Dithiothreitol (DDT)      
Enhanced Cemiluminenscene (ECEL) 
Western blotting detection reagent Amersham Pharmacia Biotech Inc 
HydrogenPeroxide 30% solution    
Pristaine (2,6,10,14-Tera-Methyl-Pentadecane)  
Sodium Dodecyl Sulfate (SDS)   USB 
TEMED (N,N,N,N’-Tetra-methyl-ethylenediamine) BioRad Labaratories 
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4.8 Equipment 
Eppendorf centrifuge 5415C     
Isotemp water bath       
Kodak Pro XO-Mat Processor   Eatman Kodak Company 
Mercury-100, UV source    Chia Technical Corperation 
Mini-Protean 3 Electrophoresis Cell System  BIORAD Laboratories 
Olympus BH-2 Electronmicroscope   Olympus 
PowerPacTM 200     Bio Rad  
PowerPacTM 300     Bio Rad  
Trans-Blot Cell System    Bio Rad  
UV 160U Spectometer    Shimadzu 
 
4.9 Other materials 
Balb/c mice, female, 5 weeks old   The Jackson Laboratories 
BIO-RAD minigel apparatus with   Bio Rad 
Spacer, 1.5 mm  
Comb, 1.5 mm, 10 lanes 
Biomax ML autoradiography film   Eatman Kodak Company  
Bright line haemocytometer    American optical 
Freund’s complete adjuvant    
Freund’s incomplete adjuvant   
ImmunoPure ® IgG Protein G Purification  Pierce 
Lab–Tek Chamber Slide System    NalgeNunc° International Corp 
Milipore transfer membranes     Milipore 
Mouse Immunoglobulin Isotyping Kit  BD PharMingen 
Nunc-ImmunoTMplate, MaxiSorpTMsurface  NalgeNunc° International Corp  
SDS-PAGE gel, 12%     Bio Rad 
Trans Blot Fiber Pads     Bio Rad  
Trans Blot Cell Gel Holder    Bio Rad  
Trans Blot Apparatus     Bio Rad  
Whatman 3 mm filter paper     
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5. Methods 
 
5.1 Cell culture maintenance 
5.1.1 Propagation of continuous cell lines (RK-13, BHK-21) 
Use a T-75 flask with a 95% confluent cell monolayer. Discard the old media and 
add 4 ml of STV-solution and rinse the cells well. This will remove the FBS that will de-
activate the trypsin. Decant the STV-solution before adding another 4 ml of fresh STV-
solution and incubate for 1-4 min at 37°C. Bang on the flask to detach the cells from the 
surface. Add 10 ml of nutrient medium, the FBS will inhibit the trypsin, mix well and 
pour into a 50 ml conical tube. Centrifuge at 1300 rpm (200 g) for 5 min at 25°C. Discard 
the supernatant and suspend the cells in 10 ml of nutrient medium.  Mix well by pipetting 
up and down to get an equal distribution of cells throughout the suspension. Transfer 1 ml 
of cell suspension into a new T-75 flask and add 20 ml of nutrient medium into the flask 
(1:10 split). Incubate the flask at 37°C for 3 days, feed on the 3rd day and split on the 7th 
day. 
Note: To get a confluent monolayer within 36-48h transfer 2 ml of cell suspension into a 
T-75 flask and add 20 ml of complete medium to the flask (1:5 split).  Generally one T-
75 flask is sufficient to seed five 96 well plates for neutralization or micro titration 
assays.  For specific cell lines: 
One T-75 flask of BHK-21 cells (confluent) is sufficient for 5-10, 96 well plates.   
One T-75 flask of RK-13 cells (confluent) is sufficient for 3-4, 96 well plates. 
For chamber slides ready to infect in 24h, take 50 µl cells from the 10 ml suspension and 
add 350 µl media per well. 
 
5.1.2 Counting cells 
Trypsinize the cells and add 10 ml of complete medium, as for propagation 
protocol. Centrifuge and suspend the cells in 10 ml of nutrient medium. Make a 1:10 
dilution of cell suspension (100 µl in 900 µl of complete medium). Take 0.5 ml of the 
diluted cell suspension into a snap cap tube and add 0.5 ml of 0.2% Trypan blue (1:2 
dilution). Load the hemocytometer and count the cells in each of the four large squares. 
 - 43 -    
Methods 
 
 
Live cells do not take Trypan blue into cell; therefore count only the transparent cells.  
Some cells will be touching the outside borders. Count only those cells touching two of 
the outside borders (e.g., the upper and left). Use the following formula to calculate the 
number of vital cells/ml.: 
Cells/ml = average number of cells per large square x 104/ml x dilution factor  
 
5.1.3 Freezing cells 
Take a T-75 flask and prepare the cells as if to pass them. Count the cells. 
Calculate the needed amount of freezing medium to get approximately 10
7 cells/ml. 
Carefully remove the supernatant and add the calculated amount of freezing medium. 
Mix the cells well. Aliquot the cells into 2 ml vials (1 ml per vial) and immediately store 
the vials in a –70°C freezer. Transfer the vials into liquid nitrogen after 2 days. 
 
5.1.4 Recovery of frozen cells 
Rapid thawing of the cells is necessary, to ensure the survival of the frozen cells 
during the recovery. Thaw the cells in the water bath at 37°C, by swirling the tube. Do 
not submerge the lid to avoid contamination of the cells, rinse the outside of the tube with 
EtOH before opening. Transfer the thawed cells immediately into a 50 ml conical with 15 
ml of nutrient medium. Centrifuge at 1300 rpm (1200 g) for 5 min at 25°C, to rinse the 
DMSO out. Aspirate the supernatant and suspend the cells in 10 ml of growth medium.  
Transfer the cell suspension into a T-75 flask and add 10 ml of medium. Incubate at 37°C 
for 2-3 days. Feed the cells with nutrient medium and split the flask when the cells are 
about 95% confluent. 
 
5.2 Cell culture and virology techniques 
5.2.1 Infection of RK-13 and BHK-21 cells with EAV 
Decant the media from two T-150 flasks of freshly confluent RK-13 cells and 
then wash the cells two times with MEM. Infect with equine arteritis virus at a M.O I. 10 
(see titration).  Suspend the virus in 20 ml (total volume) MEM. Inoculate with 10 ml of 
the virus suspension per flask and adsorb for 60 min at 37°C. 
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Add 35 ml of complete RK-13 medium per flask and incubate at 37°C for 36-48h. Freeze 
the flask in –70ºC when about 90% of the cells are dead. 
 
5.2.2 Production of working virus stock 
Take a T-75 tissue culture flask with BHK cells, which are about 95% confluent 
and split into 5x T-150 tissue culture flasks. When the T-150 flasks are about 80% 
confluent rinse them 2x with 5 ml of MEM. Inoculate the monolayers with first passage 
of EAV 030H (van Dinten, 1997). Suspend 1 ml of virus stock in 10 ml of serum free 
MEM and add 10 ml in each T-150 flask. At the same time mock infect one T-75 flask of 
BHK cells. Let the virus adsorb for 1h at 37°C. Add 40 ml of complete BHK-21 medium 
/ T-150 flask. Incubate at 37°C for 48h or until 95% - 100% CPE. Centrifuge at 3000 rpm 
(2800 g) in the tabletop centrifuge at 4°C for 15 min. Make 1 ml aliquots of supernatant 
and store at -70°C. Use one 0.5 ml frozen vial for titration of the virus. 
 
5.2.3 Plaque purification of EAV 
Make a confluent monolayer of RK-13 cells in a T-75 flask. Trypsinize the cells 
and suspend in 10 ml of RK-13 medium. A 1:5 dilution takes 24h to form a monolayer, 
1:10 dilution takes 3 days. Add 1 ml of diluted cell suspension into each well of a 6 well 
tissue culture plate and incubate at 37°C for the appropriate time. Remove the medium 
from the wells and rinse plates 2 times with 3 ml MEM. Add 3 ml of MEM to each well 
for the time of the virus dilution preparation. Thaw the virus and make ten-fold serial 
dilution in MEM (10-1 to 10-6). Use 200 µl of virus and 1800 µl of MEM. Make 
duplicates for each dilution and allow two wells of cell control per titration.  
Add 100 µl of diluted virus to each well and slowly rotate for equal distribution and 
incubate for 1h at 37°C, do not move during incubation. During the 1h incubation period 
boil 1% agarose in Earls BSS and leave it at 45°C in a water bath. Pre-warm the RK-13 
medium to 45°C in a water bath. After the 1h adsorption period, mix 1% agarose with 
pre-warmed RK-13 medium at a 1:1 ratio for 30 ml (15 ml media + 15 ml 1% agarose in 
Earls BSS). Add 4 ml of agarose and RK-13 medium mix per well and incubate at 37°C. 
After 4 days dump the media and add 2 ml of crystal violet per well. Incubate for 4h up to 
12h and remove the crystal violet by carefully rinsing the plates under running tab water. 
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Let the plates dry upside down for about an hour before calculating the plaque forming 
units (PFU). Use the following formula: 
PFU = amount of PFU x dilution factor / infectious volume  
Example 10-7   -> 21  & 34 plaques   => average of 28 plaques 
  28x107 plaque forming units / well   = 2.8x108 PFU/well 
  2.8x108 PFU/ 100 µl (infection volume) 
  2.8x109/ 1000 µl 
 
5.2.4 Serum neutralisation  
Use 96 well tissue culture plates for the test. First calculate how many plates are 
needed for each test. The test should be run with the following controls: pure virus,  
10-2,10-3 and pure cells as negative control. All samples should be run in doubles.  
Make a 10% solution of guinea pig serum in MEM. Take the tissue culture plates and put 
50 µl of the serum solution in row B – H. Dilute all samples at 1:4, mix well, and put  
100 µl in row A. Make a 2-fold serial dilution from 1:4 up to 1:512 by taking 50 µl from 
row A into row B, mix 10x by pipetting up and down. Continue up to the last row; row H, 
which will have the 1:512 dilutions. Add 100 µl of virus diluted in MEM to each well, 
except the control wells, treat them as described above. Incubate the plates for 2h. Add 
RK-13 cells, one confluent T-75 should be diluted in 30 ml of complete media. Ideally 
the wells should be confluent after 24h. Incubate at 37°C overnight and add 50 µl of 
medium next morning. Monitor the cell growth. Stop the test when the negative control 
wells are confluent. Carefully dump the media and add crystal violet to each well. 
Incubate for 4h or overnight. Rinse the wells under slow running tab water. Let the plates 
dry for at least 1h upside down. The dilution where only one or two plaques are 
recognizable is the cutting point.  
   
5.3 Production and characterization of monoclonal antibodies  
5.3.1 Collection of blood and separation of serum from blood 
Bleed mice by cutting the tip of the tail and collect the blood in Eppendorf 
centrifuge tubes. Let the blood coagulate for 1 h at 25°C. Centrifuge for 10 min at 4°C at 
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1200 g in an Eppendorf centrifuge. Transfer the serum under sterile conditions into a new 
centrifuge tube and centrifuge again for 10 min at 4°C at 1200 g. For finale storage at –
20°C transfer the serum sterile into a new centrifuge tube.  
 
5.3.2 Immunization of mice  
Before the first immunization collect blood as described above from each mouse 
as negative control serum. Inject 0.2 ml of a 1:2 emulsion of the according antigen in 
Freund’s complete adjuvant i.p.. Bleed the mice after three weeks and immunize the 
following day with a 1:2 emulsion of the according antigen in Freund’s incomplete 
adjuvant i.p.. Repeat this one more time and collect blood for a last time three weeks after 
the last immunization.  
For nsp1 immunization use 50 µg of nsp1 bacterial fusion protein.  
For nsp2 immunization use 10 µg of nsp2 bacterial fusion protein. 
For nsp4 immunization use 10 µg of nsp4 bacterial fusion protein. 
For M145 immunization use 150 µg of M145 peptide. 
For M88 immunization use 150 µg of M88 peptide. 
 
5.3.3 Thawing of P3x63Ag.8.653 cells 
Recover frozen cells from liquid N2 and thaw the cells in a 37 °C water bath, by 
swirling the tube. Suspend the thawed cells in 15 ml complete RPMI-1640 medium and 
centrifuge at 25 °C for 5 min at 1300 rpm (1200 g) in a tabletop centrifuge. Aspirate the 
supernatant and suspend the cells in 5 ml complete RPMI-1640. Transfer the cell 
suspension into a T-25 flask and add 5 ml of medium. Incubate at 37 °C for 2-3 days.  
 
5.3.4 Propagation of P3x63Ag.8.653 cells 
When the cells are 80-90% confluent they are ready to be passed. Bang the flask 
hard a few times and split the media into two bigger flasks add complete RPMI-160 
media, according to maximum media capacity of the flask. Incubate at 37 °C with 5% 
CO2.  
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5.3.5 Counting of P3x63Ag.8.653 cells 
Bang the flask to detach all the cells and to equally distribute the cells throughout 
the medium. Take 0.5 ml and make a 1:50 dilution in PBS. Take 0.5 ml of diluted cell 
suspension into a snap cap tube and add 0.5 ml of 0.2% Trypan blue, 1:2 dilution. Load 
the hemocytometer and count the live cells in each of the four large squares. Calculate the 
cells/ml. For the fusion 2x108 live cells are needed, 107 cells/ml for freezing. 
 
5.3.6 Freezing of P3x63Ag.8.653 cells 
Prepare the cells as if to pass them and count the cells. Calculate the needed 
amount of freezing medium to get approximately 1x107 cells/ml. Carefully remove the 
supernatant and add the calculated amount of freezing medium. Mix the cells well. 
Aliquot the cells into 2 ml vials (1 ml per vial) and immediately store the vials in a          
–70 °C freezer. Transfer the vials into liquid nitrogen after 2 days. 
 
5.3.7 Harvesting of mouse spleen cells and fusion protocol  
Ensure that the mouse is healthy and bleed it a final time. Now pool all available 
T-150 tissue culture flasks with P3x cells, which should be in the log phase of growth. 
Take 2 ml and make a 1:5 or 1:10 dilution in PBS for the cell count. 1.5 – 2.0x108 viable 
cells are needed for a fusion. Split the cell suspension in 50 ml conical tubes and 
centrifuge them at 1300 rpm (1200 g) for 5 min at 25 °C in a tabletop centrifuge. Decant 
the supernatant and suspend the pellets in 5 ml RPMI-1640. Pool the suspensions in one     
50 ml conical tube and bring the volume up to 40 ml. Centrifuge, as described before. 
Wash the cells two more times. Euthanise the mouse using carbon dioxide and dip the 
body in 70% alcohol. All proceeding steps should be under sterile conditions. Let the 
alcohol dry of by evaporation and then collect the spleen aseptically. Put the spleen in a 
tissue grinder and add 10 ml of RPMI-160, grind the spleen with 10 strokes. Add 35 ml 
of RPMI-1640 in 50 ml conical tube and transfer the spleen cells into the tube. Centrifuge 
the spleen cells at 1300 rpm (1200 g) for 5 min at 25 °C in a tabletop centrifuge. Decant 
the supernatant and suspend the cells in 10 ml of RPMI-1640. Make a 1:100 dilution of 
cell suspension in 3% acetic acid and count the cells in a hemocytometer. 5x107 spleen 
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cells are needed for a fusion. Centrifuge the cell suspension as above and suspend cells 
using the calculated amount of RPMI-1640. Use additional spleen cells to freeze a 
minimum of 1 vial for back up. Add 5x107 spleen cells to the P3x cells, mix them well 
and centrifuge them at 1300 rpm (1200 g) for 5 min at 25 °C. Suspend and centrifuge the 
cell mixture one more time. Aspirate the supernatant and put conical tube in a warm 
water bath. Add 1 ml of PEG over 1 min of time. Use the 1ml glass pipette and carefully 
stir the cells for a minute. Now add 2 times 1 ml RPMI over 1 min and then 7 ml RPMI 
over 3 min. After the fusion immediately centrifuge as before. Slowly suspend the cells in 
130 ml HAT medium. Transfer 5 ml of the cell suspension into a T-25 flask and incubate 
at 37 °C. Plate the cells in 12x 96 well tissue culture plates by adding 0.1 ml to each well. 
Incubate the plates at 37 °C for a week without disturbing the cells. Use the T-25 flask to 
check on the cells every other day.   
 
5.3.8 Propagation of hybrid cell line 
After a week add 100 µl HAT medium in each well. From now on check the 
plates every other day. Depending on the rate of cell death of the P3x cells and the 
growth of hybrid cells feed the plates after 3 days by aspirating half of the medium and 
adding 100 µl/well HAT medium. Feed them depending on their growth form now on 
every 2 to 3 days. When the hybrid cells cover about 50% of the wells start screening, 
under optimal condition this will be around day 21. After the first screening, when there 
are no other cells alive, start to wean the cells of the HAT medium. After the aspiration of 
100 µl medium add 75 µl HAT and 25 µl of HT medium. Increase the amount of HT over 
4 steps until the cells receive 100% HT.  
 
5.3.9 Screening of hybrids for positive cells 
Screen the wells with a microscope for hybrid growth. If 50% or more of the well 
is covered with hybrid cells collect 50 µl of supernatant. Use the IFA for a first screening 
and the Western immunoblotting assay to confirm positive results.  
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5.3.10 Expansion of hybridoma cells  
Name the hybridoma secreting specific antibodies according to their destination, 
for example 10H6. Now label 24 well tissue culture plates and add 1 ml of HT. Remove 
100 µl of supernatant from the wells, which are to be expanded, put them with 100 µl of 
HT in a new well. Mix the cells by pipetting up and down for 10 times. Transfer 100 µl 
of the suspended cells into their new destination in the 24 well plates. Incubate at 37 °C 
and feed them every 2-3 days. When the well is 50% confluent, screen the hybridoma a 
second time. Transfer the rapidly growing cells into a T-25 flask, containing 7 ml of HT 
medium. Put 200 µl of cell suspension into original well and add 1 ml HT to each well. 
Incubate plate and flask at 37°C. Feed the flask after 24-48h of incubation with 10 ml HT 
medium. Count the cells to determine the appropriate dilution for freezing. Cells in log 
phase of growth should be frozen at 1.1 x 105 cells/ml.  
 
Calculation: 
a = required amount of freezing medium 
b = volume of hybridoma suspension / T-25 flask 
c = dilution factor 
d = average of cells per square 
107 live cells/ml = 100 x 105cells/ml = required final cell concentration 
(100x105 / d) x c x a = b (ml) 
Suspend the hybridoma cells in appropriate volume of freezing medium and transfer into 
a minimum of two aliquots and store at –70 °C overnight. Transfer to liquid nitrogen for 
long-term storage after 2 days.   
 
5.3.11 Cloning of hybridoma cell lines by limiting dilution 
Take a T-25 tissue culture flask with hybridoma cells. Count the cells and 
calculate the number of viable cells/ml. Dilute the cells to get 16 cells/µl, 1600 µl are 
needed for cloning in duplicates. To be safe make more volume, optimal are 5 ml, 
therefore 800 cells are needed. 
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Calculation: 
Number of viable cells/ml = number of viable cells / square x 104 x dilution factor 
Number of viable cells/µl = number of viable cells / square x 10 x dilution factor 
 
Label the 96 well tissue culture plates and add 100 µl of HT-medium to each well. Now 
add 200 µl of the prepared cell suspension into each well in column #1 and #2. To make a 
serial dilution take 100 µl from column #1 into column #3 and from column #2 into 
column #4. Repeat this scheme 4 more times. This should lead to the following amount 
of cells in each well: 
16 cells / 100 µl in column 1 + 2 
8 cells / 100 µl in column 3 + 4 
4 cells / 100 µl in column 5 + 6 
2 cells / 100 µl in column 7 + 8 
1 cells / 100 µl in column 9 + 10 
0 cells / 100 µl in column 11 + 12 
Incubate the plate at 37 °C for 7 – 14 days. Monitor the plates under the microscope for 
cell growth. Screen all wells when the new colonies cover 50% of the well. Expand only 
confirmed positive colonies, which were started by a single cell. Expand the selected 
clones and repeat the cloning procedure two more times. Make sure that between each 
cloning back up vials are stored in liquid nitrogen.    
 
5.3.12 Production of ascitic fluid  
Use 5-week-old female BALB/c mice for the ascitic fluid production. Inject 0.5 
ml pristane i.p into each mouse and repeat this procedure after 5 weeks. The mice are 
ready for the infection with the hybridoma cells one week after the second injection. For 
the cell preparation use one T-75 flask with wanted hybridoma cell line. Bang the flask 
and collect the cell suspension in a 50 ml conical. Centrifuge 1300 rpm (1200 g) for 5 
min at 25°C, carefully aspirate the supernatant and suspend the cells in 20 ml of PBS. 
Repeat this procedure two more times. Collect 0.5 ml of cell suspension before the final 
spin and count the viable cells. For one infection 2 x 106 cells are needed, which should 
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be suspended in 0.5 ml PBS. After the cells are suspended draw 0.5 ml of the suspension 
into a 3ml syringe. Inject the whole volume i.p., using a 22 gauge 11/2 needle. After the 
infection check the mice daily. The first sing of tumor and ascitic fluid production is a 
slowly increasing belly volume. Monitor the mice carefully and kill them when they start 
to show signs of being uncomfortable. After the mouse is killed dip it in 90% alcohol for 
10 seconds and let the alcohol dry off. The following steps should be performed under 
sterile conditions. Separate the skin from the abdomen muscles and carefully insert a 22 
gauge 11/2 needle into the abdomen cavity.  If the tension on the belly is too high, the 
tissue can rupture. Aspirate the ascitic fluid and collect it in a 50 ml conical. Spin at 
2600g for 10 min at 4°C. This will separate the blood cells from the ascitic fluid. Aspirate 
the supernatant and centrifuge it at 1400 rpm (1600g) for 20 min at 4°C. Remaining 
pristane should be floating on top of the ascitic liquid, carefully collect the ascitic fluid 
leaving the pristane behind. For long-term storage at –20°C degree aliquot the ascitic 
fluid into 2 ml vials. 
 
5.3.13 Purification of MAb 
Allow protein G column and ImmunoPure ® (G) Buffers to warm to room 
temperature. Open a protein G column by carefully removing the top cap first. This 
prevents air bubbles from being drawn into gel. Pour off the storage solution and 
equilibrate the protein G column with 5 ml of ImmunoPure ® (G) Binding Buffer. If the 
samples are serum, ascitic fluid or tissue culture supernatant, it is necessary to dilute 
samples at least 1:1 with ImmunoPure ® (G) Binding Buffer. This is necessary to ensure 
that the proper ionic strength and pH are maintained for optimal binding. Apply up to 4 
ml of the diluted sample to the protein G column and allow the sample to flow 
completely into the gel. The flow of buffer will stop automatically when the liquid level 
reaches the top frit. Wash the protein G column with 10 ml of the ImmunoPure ® (G) 
Binding Buffer. Take 2 ml fractions by applying 5 x 2 ml aliquots of binding buffer. 
Elute the bound IgG with 6 ml of ImmunoPure ® (G) Elution Buffer. Collect the elute in 
1 ml fractions in 2 ml glass tubes which contain 100 µl of 500mM Tris buffer. This raises 
the pH of the protein fractions immediately to neutral. Take 10 µl from each of the 
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collected samples and make a 1:10 dilution. Monitor the elution of bound proteins by 
absorbance in a photo-spectrometer at 280 nm. The eluted immunoglobulin fractions can 
now be desalted over an Excellulose™ Desalting Column. Apply up to 1.25 ml of 
purified immunoglobulin to the equilibrated column. By applying the immunoglobulin 
fractions to the Excellulose™ column, desalting and/or buffer exchange can be 
accomplished. For desalting, use a buffer such as PBS in the equilibration and washing 
steps. Apply 10 x 1 ml aliquots of the equilibration buffer to the column and collect 1 ml 
fractions. Protein concentration can be monitored by absorbance at 280 nm. Use the 
following formula to calculate the Ab concentration per ml: 
Ab mg / ml= (spec. reading x dilution) / 1.4   
Regenerate Excellulose™ Columns by passing 20 ml of PBS through the column. For 
storage, the column should be washed with 10 ml of water containing 0.02% sodium 
azide and then capped when approximately 2 ml remain. Regenerate the Protein G 
Column by washing with 5 ml of ImmunoPure ® (G) Elution Buffer. If the column is to 
be stored, wash the column with 0.02% sodium azide in water and make sure that about 2 
ml of solution remain when column is sealed. Store columns and buffers refrigerated. 
 
5.3.14 Mouse immunoglobulin isotyping ELISA 
Bring all reagents of the mouse immunoglobulin isotyping ELISA Kit to room 
temperature before use. Prepare the buffers and Antigen Mixture as followed: 
- Coating Buffer: Dilute required quantity of 10x PBS with distilled water (50 ml/plate) 
- Blocking Buffer: Dilute required quantity of 10% BSA 1:10 with 1x PBS (35 ml/plate). 
- Dilute Positive Reference Antigen Mixture 1:50 with Blocking Buffer (1ml/plate). 
- Dilute HRP-labeled rat anti-mouse Ig MAb 1:100 with Blocking Buffer (10 ml/plate). 
- Substrate Solution: Within 15 min prior to use, mix equal volumes of Substrate Reagent 
A and B (5 ml of each solution for each plate) in a clean glass tube or flask.  
The required amounts of the purified coating antibodies should be diluted immediately 
before use. Dilute an appropriate amount of each isotype-specific rat anti-mouse purified 
MAb in Coating Buffer and deliver 50 µl of each reagent to applicable rows. Tap the 
plate gently to ensure even distribution of antibody solution on the bottom of wells. 
Incubate the covered plate, at 36°C for 1h or at 4°C overnight. Use washing solution 
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(0.05% Tween-20 in PBS) to wash out plate contents. Then shake out remaining contents 
and blot excess on a clean paper towel. Repeat the wash 3 times. Add 200 µl of blocking 
buffer to each well and incubate at room temperature for 30 min. Wash 3 times, shake out 
the blocking buffer, and blot dry. Pipette 100 µl of each hybridoma culture supernatant to 
be tested to appropriate plate columns and incubate for 1 hour at room temperature. 
Positive controls should be included as desired; negative controls generally consist of 
parent myeloma culture supernatant. After 1h wash 3x, shake out remaining contents, and 
blot dry. 
Add 100 µl of HRP-labeled rat anti-mouse Ig MAb solution to each well, and incubate at 
room temperature for 1h. Wash 6 times, soaking the wells for 30 seconds to 1 min on 
each wash. Thorough washing at this step is very important. Add 100 µl of prepared 
Substrate Solution to each well and incubate plate for 3 – 10 min at room temperature. 
Positive reaction wells will develop a greenish-blue color. Negative wells will be 
colorless. Pipette 50 µl of stop solution to each well. Positive wells will become yellow. 
Read visually.  
 
5.4 Molecular Biology 
5.4.1 Characterization of EAV expressed proteins 
Prepare 6 T-150 tissue culture flasks by seeding BHK cells. When the monolayer 
is about 90% confluent rinse each flask 3 times with MEM. Infect each flask with 1 ml of 
EAV.030H working stock. Incubate for 1h at 37°C.  After feeding each flask with 40 ml 
of nutrient media incubate them for 48h at 37°C. Aspirate the supernatant and add 15 ml 
of the solubilization buffer. After an incubation period of 15 min at 4°C the monolayer 
should start to detach from the flask surface. Use a 10 ml pipette to rinse the liquid up 
and down to ensure that all cells are collected. Pour the buffer into a 50 ml conical and 
centrifuge at 1400 rpm (1600 g) for 15 min at 4°C. Aliquot the supernatant in 1 ml 
portions in Eppendorf tubes and store them at –80°C.  Control antigen was prepared as 
described above, except that the flask was mock infected with MEM.  
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5.4.2 Immunofluorescence assay  
Prepare a T-75 tissue culture flask with a 90 % confluent BHK-21 monolayer as 
to pass. After the resuspension in 10 ml of growth medium take 1 ml and dilute it further 
in 10 ml of growth medium. Seed 200 µl of the cell suspension in each chamber of the 
Lab–Tek Chamber Slide System. Incubate the slides at 37°C for 12h. Carefully aspirate 
the medium out of each well. Add 100 µl of fresh medium to the bottom row of each 
slide; these are the negative control chambers. Infect the 4 chambers of the top row with 
100 µl of final virus dilution in MEM. Incubate for 1h at 37°C and ad 200 µl of complete 
BHK medium to all chambers. Incubate the slides for 12h. The following steps can be 
proceded at the workbench. Aspirate the medium and wash each well 1 time with PBS. 
Handle the uninfected chambers first. Add fixative 200 µl per chamber and incubate for 
1h at 4°C. Rinse all chambers 3 times with wash solution and afterwards permeabilize 
with 200 µl of permeabilization solution for 5 min at 25°C. Thoroughly rinse the slides 3 
times with wash solution. The slides are now ready for the assay. 
Add 50 µl of the Primary antibody diluted in antibody dilution solution. After the 
incubation for 1h at 25°C rinse the slides 3 times with wash solution. Add 50 µl of 
secondary Ab diluted in antibody dilution solution. Repeat the incubation and wash step. 
Let the slides dry and remove the chambers. Place 3 drops of the DAKO Fluorescent 
Mounting Medium on the glass slide and cover it with a matching cover slip. For the best 
results the slides should be examined right away under a fluorescent microscope. Kept in 
the dark at 4°C the fluorescence will be visible for about a week.  
 
5.4.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis of proteins 
Assemble the minigel apparatus: Wash glass plates and spacers with distilled 
water.  Air dry in a rack.  The glass plates must be absolutely clean.  Just before 
assembly, wipe the glass plates with 70 % ethanol.  Assemble glass plates with 1.5 mm 
spacers in between on to the Plexiglas holders (large glass plate should be against the 
Plexiglas).  The screws must be tight enough to prevent leaks.  Mount the Plexiglas 
holders on to the gel-casting stand (small glass should face out).  Snug the Plexiglas 
holder tightly into rubber pad in the bottom of the gel-casting stand. Use a 12 % resolving 
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gel for viral proteins and a 4 % stacking gel. The total volume is 50 ml for resolving gel, 
and 25 ml for stacking gel (sufficient for 4 minigels).   
Ingredients     12 % Resolving Gel 4% Stack. Gel  
30% Acrylamide/Bis solution 37.5:1 ratio  20 ml   3.3 ml 
0.5M Tris HCl, pH 6.8    -   6.3 ml 
1.5 M Tris HCl, pH 8.8    12.5 ml  - 
10% SDS      500 µl   250 µl 
dH2O       16.75 ml  15 ml 
TEMED      25 µl   25 µl 
10% Ammonium persulfate    250 µl   125 µl 
TOTAL      50ml   25ml 
First make up gel solutions without 10 % ammonium persulfate (10 % APS) and TEMED 
and degas for 5 min (air inhibits polymerization).  Keep the gel solutions in vacuum 
chamber until needed. Add fresh 10 % APS and TEMED to the resolving gel solution to 
initiate polymerization, mix well. Pour about 7.5 ml of resolving gel into the glass mold 
up to 1 cm below the top of the smaller glass plate (this 1 cm is to pour the stacking gel).  
Carefully add distilled water over the resolving gel with a Pasteur pipette to avoid contact 
with air.  Allow one hour for polymerization at room temperature. The resolving gel can 
be poured the day before if overlaid with distilled water and covered with plastic wrap. 
When gels are polymerized, pour off water. Add 10 % APS to stacking gel, mix and 
immediately pour over the top of the resolving gel. Add until close to the top. Place 
combs (before placing the combs should be washed with warm water and dried) in to the 
stacking gel (stop 3-5 mm above the inter phase of stacking and resolving gels). Avoid air 
bubbles. Allow 15 min for polymerization (during this time get the samples ready). 
Remove combs.  Air bubbles should run in to replace combs. Alternatively use pre-
poured gels, acquired from a commercial source (BioRad). 
Make up one liter of 1x SDS-PAGE running buffer and pour 500 ml into the buffer tank.  
Remove the gels (molds with the Plexiglas holders) from the casting stand and lock into 
the central unit with thumbs pushing from the bottom. The small glass plate goes against 
the rubber gasket.  Bottom clicks into place on base plate of the central unit. Drop the 
assembly unit into the buffer tank. Add running buffer to the center compartment to the 
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maximum. Do not allow inside buffer and buffer in the tank to communicate (not 
imperative). Flush out each of the wells with pipette before loading the samples.   
Preparation of Samples and Running the Gel: Denature protein in sample buffer (with the 
appropriate concentrations of DTT) by boiling for 1-3 min. The samples can be stored at 
–20°C. If samples were frozen, bring them to room temperature and boil again to get SDS 
to come into solution. The loading volume for a 10-lane comb is 30-35 µl per lane. Use 
long slender pipette tips and gently eject the sample into the well made by the comb.  
Load sample buffer into lane 1 and 10 to ensure a nice clean gel. Load appropriate 
molecular weight markers to the second lane. Proteins are negatively charged and they 
migrate to the anode at the bottom.  Run at 100 V, 30 mA (For two minigel units use 60 
mA). Running time is about 45-60 min. Stop when the dye front reaches the bottom.  
Mark the left side of the glass plates with a “Sharpie” pen to indicate lane one. Take the 
plates apart and cut the corner of the gel with a blade for identification. Gels are now 
ready for western immunoblotting transfer.  
 
5.4.4 Western immunoblotting assay 
Separate the proteins according to their molecular weight by running on a SDS-
PAGE gel. Cool the cooling unit to 4°C (put it in the refrigerator 2-3h before use). 
Remove the gels from the glass plates.  Before removing mark the top and bottom left 
hand corners (top - gel one, top and bottom - gel two).  Immerse the gels in transfer 
buffer until they are laid on to the Millipore transfer membrane. Cut the Millipore 
transfer membranes to the required size. Mark the right hand top corner with the gel 
number using a dull pencil. The Millipore membranes are hydrophobic.  Soak first in 
methanol for 2-3 seconds, transfer to distilled H20 and allow the paper to wet by capillary 
action, transfer to transfer buffer. Cut the filter paper, Whatman 3 mm, to the required 
size.  Just before use, dip the filter paper in transfer buffer. 
Assemble the transfer sandwich fiber pads / gel / membrane / fiber pads, keep all the 
components wet and make sure the sandwich is tightly assembled. Place the complete 
sandwich in the transfer buffer tank with the membrane closest to the positive electrode, 
the anode. Make sure hat the stir bar still is able to operate. 
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Transfer for 45 min at 0.66 amps (80/100V) or overnight at 0.22 amps at 4ºC. Keep a 
magnetic stirrer in the transfer buffer tank and leave on a stir plate. After transfer 
disconnect the power supply. Disassemble the sandwich and mark the membrane by 
clipping one corner or by marking wholes using a pin. Rinse the membranes several 
times with TBS-T (2-3 quick rinses) and wash for 10 min on the rocker. Add the blocking 
buffer and incubate at room temperature for 1h, the membranes can be left in the 
blocking solution overnight, rocking at 4ºC. Remove the blot membrane from the 
blocking solution and wash with TBS-T washing buffer. Briefly rinse the membranes 
with three changes of washing buffer, then wash once for 5 min with fresh changes of the 
washing buffer at room temperature. 
During washing dilute the primary Ab in Western Immunoblot Protein dilution buffer 
(ADB).  Use tissue culture supernatants either undiluted or at a 1:10 dilution. Serum 
should be diluted at 1:200, ascitic fluid 1:1000. Purified IgG should have a concentration 
of 10 µg/ml. Incubate the blot in diluted primary antibody for 1 hour at room 
temperature. Wash as before. During the washing step dilute the biotinylated secondary 
antibody (biotinylated goat anti-rabbit or biotinylated goat anti-horse IgG (H+L) 
immunoglobulin) 1:10,000 in ADB.  Incubate the membrane in the diluted secondary 
antibody for 1h at room temperature. Wash with TBS-T washing buffer. Briefly rinse the 
membrane in three changes of washing buffer, then wash three times for 10 minutes with 
fresh changes of the washing buffer at room temperature. In general, Avidin-HRP 
conjugates should be used at concentrations of 0.5-5 µg/ml which in this case is a 1:2000 
dilution of the commercial stocks. Reagents labeled with horseradish peroxidase should 
be diluted with conjugate dilution buffer (CDB). Add conjugates to the membrane and 
incubate at room temperature for 45-60 min. Wash the membrane as directed before. 
During these washes, make sure the developer is warmed up. 
Take the ECL (Enhanced Chemiluminescence) detection reagents supplied and mix an 
equal volume of detection solution 1 with detection solution 2 to give sufficient to cover 
the membranes (final volume required is 0.125 ml/square cm membrane). Drain the 
excess buffer from the washed blots and place them in fresh containers. Add the blots to 
the detection reagent directly; do not let the blots dry out.  Incubate for precisely 1 min at 
room temperature. Drain off excess detection reagent by holding the blot vertically and 
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touching the surfaces with a disposable pipette and wrap blots in Saran Wrap. Avoid air 
pockets. 
Place the blots, protein side up, in the film cassette, and tape them in. For good results 
minimize the delay between incubating the blots in detection reagent and exposing them 
to the film. Take the film and cassette to the dark room and carefully place a sheet of 
autoradiography film on top of the blots, close the cassette and expose for 15 seconds.  
Do not move the film whilst it is being exposed. Try a very brief exposure as well as one 
up to 1- 15 min. ECL is very sensitive, longer exposures should not be necessary. 
 
5.4.5 d-ELISA  
Number the needed amount of Nunc Nalge° 96 well certified Maxisorp ELISA 
plates. Each sample should be tested in doubles on positive and negative antigen. The 
row H will be used for the positive control, nsp1, the negative control, O16 MAb BTV, 
and a blank. Make a 1:9 dilution of the antigen in coating buffer and coat the plates by 
adding 100 µl of the antigen dilution. Tap the plate gently to ensure even distribution of 
antibody solution on the bottom of wells. Cover the plate with plate sealer and incubate 
overnight at 4°C. Then shake out remaining contents, and blot excess on a clean paper 
towel. Block unbound sites by adding 200 µl of blocking buffer per well and incubate for 
1h at 37°C. Swiftly dump the blocking buffer and wash each well with wash buffer from 
a squirt bottle three times. Before adding the primary antibody at 50 µl per well blot 
excess on a clean paper towel.  
Use the following dilution in blocking buffer for the different primary Antibodies: 
BTV O16 MAb with 4 µg/ml, 
nsp1 MAb 12A4 with 4 µg/ml 
3E2 ascitic fluid 1:8000 
M antipeptide sera 1:600. 
Now incubate for 1h at 37°C. Repeat the above described washing step every time before 
adding new solution to the plates. Dilute the secondary antibody, biotinylated-Goat Anti-
Mouse IgG or biotinylated-Goat Anti-Rabbit IgG (H+L), 1:10000 in blocking buffer. 
Add 50 µl/well and incubate for 1h at 37°C. Add 50 µl/well of Streptavidin-HRP 
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conjugate, 1:2000 in blocking buffer, and incubate for 1h at 37°C. Prepare the substrate 
solution immediately before the use. Add 100 µl/well of substrate solution. Stop the 
reaction with 50 µl of 1 % SDS solution after 15 min.  The optimal signal reading of 
Streptavidin-HRP is at 480nm. Read the optical density (OD) of the plates at the UV max 
Kinetic microplate reader. 
 
5.4.6 c-ELISA  
Prepare the plates up to the first wash step as described for the d-ELISA. Add 50 
µl of the equine serum to be tested in each well and incubation of 1.5h at 37°C. Wash 
carefully and thoroughly after the incubation time. Add 50 µl of MAb 12A4 (nsp-1), 
MAb 3E2 (N), or rabbit anti-peptide sera (M), as the competing antibody to determine the 
ability of the test horse serum (inhibitory antibody) to block the binding of each of the 
various EAV protein-specific antibodies. For the dilution of each Ab see results of the d-
ELISA. The protocol of the c-ELISA is otherwise identical to that for d-ELISA.  The 
correlation between OD values and log SN titers were determined by linear regression 
and correlation analysis using the SPSS 11.0 statistical analyze program. 
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6. Results 
 
6.1. Production of antibodies to nsp1, 2, 4 and the M protein of EAV  
6.1.1 Production of MAbs to nsp1 of EAV 
3 four-week-old, female, BALB/c mice were injected i.p. 3-times at a 21-day 
interval with 50 µg of non-structural protein 1 (nsp1) recombinant bacterial fusion 
protein. Before each injection the mice were bled and the serum was tested by Western 
immunoblotting assay. Mouse C10M1 showed a positive reaction on day 21- after the 
first immunization. Mouse C10M2 and C10M3 seroconverted to nsp1 after the first 
boost, on day 42. After the final second boost, all 3 mice were confirmed positive for 
antibody to nsp1 by both, IFA staining (Figure 2) and Western immunoblotting assay 
(Table 1). 
 
 
Table 1:  Western immunoblotting assay of the collected serum samples from 3 mice, 
C10M1, C10M2, and C10M3, immunized with nsp1 recombinant bacterial fusion 
protein. The intensity of the band is represented by the symbols: - negative; + weak 
positive; ++ positive; +++ strongly positive    
 
Time point of blood collection Mouse C10M1 Mouse C10M2 Mouse C10M3 
Day 0 - - - 
Day 21 + - - 
Day 42 ++ + + 
Day 63 +++ ++ ++ 
 
 
 The mouse with the strongest reaction, C10M1, was killed and its spleen harvested. 
Fusion of splenic lymphocytes with P3x murine myeloma cells was done in order to 
create hybridoma cell lines secreting MAbs against nsp1. At day 24 after the fusion all 12 
96 well tissue culture plates were visually checked for hybridoma growth and the wells 
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with hybridoma growth identified. Tissue culture fluid supernatant was collected from the 
164 wells that showed hybridoma growth and tested by IFA. Of the 164 selected wells 23 
were positive by IFA staining and thus selected for expansion. Throughout the 3 cloning 
steps all but three wells lost their capability of antibody production. Those three wells, 
12A4a11b3f2 (12A4), 7G9f11g5 and 7G9f11g7 (7G9), were confirmed to produce MAbs 
to the nsp1 protein of EAV by IFA and Western immunoblotting assay after each cloning 
step.  
   
Figure 2: Immunofluorescence staining assays of EAV-infected and mock-infected 
BHK-21 cells. The infection was stopped after 12 hours and MAb 12A4 (nsp1-specific) 
and a rabbit anti-nsp1 serum were used as antibodies. Both show a nuclear staining 
pattern typical for the localization of nsp1 in the infected BHK-21 cells. The mock-
infected BHK-21 cells show no staining.    
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To determine the immunoglobulin isotype of the MAbs 12A4 and 7G9, purified 
supernatant of each MAb was tested with the Mouse Immunoglobulin Isotyping kit from 
BD PharMingen. Each MAb was tested in duplicate. Both MAbs were identified as IgG1 
kappa visually by the greenish-blue color the wells developed.  
Immunofluorescence staining of EAV infected BHK-21 cells with MAb 12A4 
produced strong perinuclear and nuclear staining. This finding is consistent with the 
localization of the nsp1 protein in EAV-infected cells (Tijams et al., 2002). 
 The MAb 12A4, as well as the monospecific rabbit anti-nsp1 serum, strongly 
reacted by Western immunoblotting assay with a 29K protein in the lysate of EAV-
infected BHK-21 cells (Figure 3). 
 The result of the IFA and Western immunoblotting assays was confirmed by 
immunoprecipitation carried out in the laboratory of Dr. Eric J. Snijder, Leiden Medical 
Center, Netherlands. 
For further studies the IFA and Western immunoblotting results of all 3 MAb’s 
were compared and the MAb with the strongest fluorescence and the most visible band in 
the Western immunoblotting assay, MAb 12A4a11b3f2 (Figure 2, 3) was selected. 
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Figure 3: Western Immunoblotting assay of MAb 12A4 
Immunoblotting of gradient purified EAV (1), mock infected BHK-21 cell lysate (2) and 
lysate of BHK-21 cells infected with EAV.030H (3). The antibodies used in each lane are 
indicated below the lanes. The EAV proteins and their molecular weight are indicated on 
either side of the panel.  
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6.1.2 Production of antibodies to nsp2 of EAV 
10 µg of non-structural protein 2 (nsp2) recombinant bacterial fusion protein was 
injected i.p. 3-times at 21-day intervals into 3 four-week-old female BALB/c mice. The 
mice were bled immediately prior to each injection and their serum was tested by 
Western immunoblotting assay. One of the mice, C11M3, tested positive for antibodies to 
nsp2 on day 21after the first immunization. All mice showed a weak positive reaction 
after the first boost (day 42) and 3 weeks after the final boost (day 63). Mouse C11M3 
showed a strong positive reaction, whereas mice C11M1 and C11M2 displayed weak 
reactions (Table 2). Serum obtained after the third immunization of all 3 mice was 
confirmed positive for antibody production by IFA assay. 
 
 
Table 2:  Western immunoblotting of the serum samples collected from mice C11M1, 
C11M2 and C11M3, which were immunized with nsp2 recombinant bacterial fusion 
protein. The intensity of the band is represented by the symbols: - negative, + weak 
positive, ++ positive, +++ strongly positive    
 
Time point of blood collection Mouse C11M1 Mouse C11M2 Mouse C11M3 
Day 0 - - - 
Day 21 - - + 
Day 42 + + + 
Day 63 + + +++ 
 
 
 
 
6.1.3 Production of antibodies to nsp4 of EAV 
In order to produce antibodies against non-structural protein 4 (nsp4) 3 four-
week-old, female, BALB/c mice were injected i.p. 3 times with 10 µg of non-structural 
protein 4 (nsp4) recombinant bacterial fusion protein with an interval of 21 days. Serum 
collected immediately prior to each injection was tested by Western immunoblotting 
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assay, and all mice developed antibodies to nsp4 by day 42. After the second boost (day 
63) the mice C12M2 and C12M3 had a stronger reaction in the Western immunoblotting 
assay than did mouse C12M1. Serum collected from the mice on day 63 was tested by 
IFA to confirm the results of the Western immunoblotting assay. The staining of the 
infected BHK-21 cells in the IFA assay confirmed all 3 mice had developed antibodies to 
nsp4 (Table 3). 
 
 
Table 3:  Western immunoblotting of serum collected from mice C12M1, C12M2, 
C12M3 that were immunized with nsp4 recombinant bacterial fusion protein. The 
intensity of the band is represented by the symbols: - negative, + weak positive, ++ 
positive, +++ strongly positive.   
 
Time point of blood collection Mouse C12M1 Mouse C12M2 Mouse C12M3 
Day 0 _ _ _ 
Day 21 _ _ _ 
Day 42 + + + 
Day 63 + ++ ++ 
 
 
 
 
6.1.4 Production of MAbs to the M protein of EAV 
Two M-protein specific synthetic peptides, M88 (antigenic region) and M145 
(carboxyterminal region), were selected as antigen for the immunization of mice in an 
attempt to create MAbs to the M-protein of EAV. A regime of 3 immunizations, with an 
interval of 21 days, of 4 four-week-old BALB/c mice was carried out for each peptide. 
Initial immunization consisted of 150µg of each synthetic peptide that was diluted in 
Freund’s complete adjuvant, and subsequent immunizations included similar amounts of 
each peptide in Freund’s incomplete adjuvant that was injected i.p. into the mice. Blood 
was drawn prior to the first injection and before each boost, and at day 63 after initial 
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immunization. All sera were tested by Western immunoblotting assay. None of the serum 
samples contained antibodies to the M protein, thus both approaches failed to induce 
antibody production to the M protein in any of the mice. Thus, MAbs were not produced 
to the M protein and an M protein-specific polyclonal rabbit antipeptide serum was used 
in all subsequent assays. 
 
 
 
6.2 Development of a d-ELISA using the nsp1 MAb 
To identify the optimal dilution of the ELISA antigen a preliminary screening 
titration was performed. Briefly, infection of BHK-21 cells with EAV.030H was 
terminated at 12, 24, 36, 48, and 60 hours post infection by solubilization. The protein 
solution was clarified by centrifugation at 1600g for 15 min at 4ºC. Serial dilutions, 
ranging from 1:1 to 1:10, of the antigen preparations collected at the 5 different time 
points were tested in a d-ELISA with MAb 12A4 (Graph 1).  
The lowest readings of all samples were obtained from the antigen preparation 
that was harvested at 12 hours after infection. Higher values were obtained using antigen 
harvested at later intervals after infection, and antigen dilutions of 1:1 to 1:10 were 
compared to determine the optimal antigen source. The best results were obtained with 
antigen that was harvested at either 48 or at 60 hours after infection, and the optimal 
antigen dilution was either 1:4 or 1:6.  
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Graph 1: Time point titration of the ELISA antigen  
The infection of BHK-21 cells with EAV.030H was terminated at 12, 24, 36, 48, and 60 hours post infection (bar lower left corner) 
and tested at different dilutions using MAb 12A4 as antibody. The reading of the 1:04 dilution of the 12-hour antigen preparation was 
0.00. 
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Based on data obtained in the preliminary screening, EAV-infected BHK-21 cells 
that were harvested 48 hours after infection were selected as the antigen source for the 
ELISA. Thus BHK-21 cells were infected with EAV.030H and harvested after 48 hours, 
clarified by centrifugation and stored in 1 ml aliquots at -80ºC. This stock was used as an 
antigen source for all subsequent ELISA’s.  
To further optimize the d-ELISA, a checkerboard titration of the antigen in 
combination with the MAb 12A4 was performed (Graph 2). 6 different antigen dilutions 
from 1:1 to 1:10 were used to determine the optimal antigen concentration. MAb 12A4 
was tested at 7 different concentrations ranging from 0.1 µg to 10 µg/ml.   
The highest OD readings obtained with each MAb dilution consistently were 
obtained at the highest (1:10) antigen dilution. 
Based on these data, a 1:9 dilution of the antigen stock harvested 48 hours post 
infection with EAV.030H and MAb 12A4 at a concentration of 4 µg/ml was used in all 
assays.   
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Graph 2: Determination of the optimal coating concentration by checkerboard titration of antibody and antigen 
The antibody, MAb 12A4, was used at different concentrations ranging from 0.1 µg/ml to 10 µg/ml. The antigen, BHK-21 cells 
harvested 48 hours after infection with EAV.030H, was tested at dilution ranging from 1:1 to 1:10.  
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6.3 Screening of other protein specific MAbs with the d-ELISA 
After the optimization of the d-ELISA with MAb 12A4, other available EAV-
specific antibodies were tested by checkerboard titration. 17 GL-protein specific MAbs 
(Balasuriya et al., 1995), MAb 3E2 that is specific to the N protein (MacLachlan et al., 
1996), and a polyclonal M-serum specific to the M protein (MacLachlan et al., 1998) 
were evaluated. All MAbs tested reacted specifically with BHK-21 cells infected with 
EAV030H. The OD readings obtained with the 17 GL-protein specific MAbs were not 
sufficient for their use in a c-ELISA (Table 4). In contrast, the N protein specific MAb 
3E2 and the M-protein specific rabbit antipeptide serum reacted strongly with the antigen 
and gave high OD readings. MAb 3E2 was tested with a serial dilution ranging from 
1:1000 to 1:1024000 (Graph 3) and a dilution of 1:8000 was determined to be optimal. 
The polyclonal M-serum was tested in a serial dilution ranging from 1:100 to 1:1000 
(Graph 4) and a dilution of 1:600 was chosen for further testing. 
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Table 4: OD values of GL-protein specific MAbs in a d-ELISA using the standard 
antigen preparation. 
 
GL protein specific MAb Dilution 1:10 Dilution 1:100 
1H7 -0.022 -0.001 
1H9 -0.001 0.002 
2B3 0.005 0.006 
3F4 0.029 0.012 
5E8 -0.015 -0.003 
5F3 0.053 0.066 
5G11 0.061 0.041 
6A2 -0.001 -0.002 
6D10 0.002 0.000 
7C5 0.029 0.049 
7E5 0.017 -0.012 
7D4 -0.009 -0.011 
8D4 -0.040 -0.038 
9F2 -0.008 0.001 
10B4 0.011 -0.003 
10H4.F9 0.011 -0.003 
10F11 0.000 -0.005 
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Graph 3: Checkerboard titration of the N-protein specific MAb 3E2 
The N-protein specific MAb 3E2 was tested in a serial dilution ranging from 1:1000 to 1:1024000. The standard antigen preparation, 
BHK-21 cells solubilized 48 hours post infection with EAV.030, was used at a dilution of 1:09. 
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Graph 4: Checkerboard titration of the rabbit anti-M serum 
A serial dilution of the rabbit anti-M serum, ranging from 1:100 to 1:1000, was tested in a checkerboard titration with the standard 
antigen preparation; BHK-21 cells solubilized 48 hours post infection with EAV.030H, at a dilution of 1:09. 
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6.4 Development of a c-ELISA 
A panel of six equine sera with high SN titers to EAV (EAV SN-positive) as well as six 
SN-negative equine sera were evaluated for their ability to block the binding of EAV 
protein–specific MAbs 12A4 (nsp1), 3E2 (N) and rabbit anti-M serum (Table 5). All 3 
MAbs were used at the concentrations determined in the previous d-ELISAs. The six 
EAV SN-positive equine sera did not consistently inhibit the binding of MAb 3E2 in the 
respective c-ELISA, whereas 3 of the six positive equine sera showed an inhibition of 
MAB 12A4. The inhibition was less then 50%, and a further testing with 6 different SN-
positive equine sera verified the initial results. An inhibition of less then 50% with only 
half of the SN-positive equine sera was determined to be insufficient and therefore no 
further testing with MAb 12A4 in a c-ELISA was conducted. In contrast, all six SN-
positive equine sera strongly inhibited the binding of the rabbit anti-M antiserum (Graph 
5), whereas all EAV SN-negative equine sera did not. This shows that antibodies in these 
SN-positive equine sera either recognized the same epitopes as the rabbit anti-M 
antiserum or sterically interfere with the binding of the rabbit anti-M sera. 
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Table 5: Evaluation of the ability of six EAV SN-positive and six SN-negative sera to 
block the binding of the EAV protein–specific MAbs 12A4, 3E2 and rabbit anti-M sera. 
SN titers of the equine sera and OD readings of the c-ELISAs.  
 
Equine sera SN titer OD readings   
  Rabbit anti-M 12A4 3E2 
Ajusco 0 0.12 0.10 0.11 
Alaoin 0 0.13 0.12 0.13 
Ragtaza 0 0.12 0.13 0.09 
Guaira 0 0.14 0.11 0.10 
Gibraltar 0 0.13 0.10 0.13 
Tequilla 0 0.14 0.12 0.15 
Pos 1:128 0.06 0.10 0.14 
297 1:512 0.00 0.11 0.21 
NVSL 1:256 0.02 0.07 0.15 
I’m a pro 1:256 0.02 0.08 0.09 
M-Platano 1:256 0.00 0.07 0.12 
Googie 1:1024 0.02 0.12 0.11 
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Graph 5: Preliminary c-ELISA screening of 6 equine sera, positive by SN, for their ability to block the binding of EAV protein–
specific MAbs 12A4, 3E2 and rabbit anti-M serum. The standard antigen preparation, BHK-21 cells solubilized 48 hours post 
infection with EAV.030H, was used at a dilution of 1:09. 
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To determine the specificity and the sensitivity of the M protein-specific c-ELISA 
a panel of 100 equine sera was tested, including 50 SN-negative (Graph 6) and 50 SN-
positive sera (Graph 7). The cut-off point for a positive equine serum is 1:4 by SN test. 
The SN titers of the 50 positive sera used in this experiment are shown in Table 6. None 
of the 50 SN-negative equine sera inhibited the binding of M protein-specific antiserum 
(OD > 0.09 [0.09-0.18]) in the c-ELISA (Graph 7). Forty-three (86%) of the SN-positive 
sera clearly inhibited the binding of rabbit anti-M serum in the assay (OD < 0.08).  Seven 
sera (14%) gave high OD values (>0.08) and were thus classified as false negatives by 
this c-ELISA.  At a cut off OD value of 0.08 the sensitivity and specificity of the assay 
were 86% and 100% respectively.  Regression analysis of OD values in the ELISA 
demonstrated a strong and significant correlation to the SN titers of the same sera (r2 = 
0.82)(Figure 4). 
 
 
Table 6: Number of equine sera used in the c-ELISA listed by the SN titers 
SN titer Total 
number of 
equine sera 
Numbering 
of equine 
sera 
< 1:04 50 1-50 
1:16 3 51-53 
1:32 5 54-58 
1:64 11 59-69 
1:128 10 70-79 
1:256 11 80-90 
1:512 9 91-99 
1:1024 1 100 
 - 78 -    
Results 
 
 
 - 79 -    
Graph 6: M protein-specific c-ELISA with 50 SN-negative equine sera 
The standard antigen preparation, BHK-21 cells solubilized 48 hours post infection with EAV.030H, was used at a dilution of 1:9. 
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Graph 7: M protein-specific c-ELISA with 50 SN-positive equine sera  
The 50 positive sera used in this experiment had the following SN titers: #51-53 1:16; #54-58 1:32; #59-69 1: 64; #70-79 1:128;    
#80-90 1:256; #91-99; #100 1:1024. The standard antigen preparation, BHK-21 cells solubilized 48 hours post infection with 
EAV.030H, was used at a dilution of 1:9. The OD value of equine serum #54 and #91 was 0.00. 
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Figure 4: Regression analysis (r2= 0.82) of the relationship between the SN titer and c-ELISA OD A490 values for 100 equine sera. 
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7. Discussion 
 
7.1 Production of Mabs to nsp1 and antibodies to nsp2 and 4 
MAbs have emerged as important diagnostic and research tools in modern 
research. The usefulness of MAbs stems from three characteristics; their highly specific 
binding, homogeneity, and their ability to be produced in unlimited quantities. The fact 
that impure antigens can be used to produce specific antibodies of such qualities makes 
them even more valuable. 
In the 70’s Koehler and Milstein (1976) showed that antibody secreting cell 
clones could be readily established and maintained in vitro. The two partners in a fusion 
are B-lymphocytes, isolated from immunized animals and myeloma cells. Hybridomas 
can be prepared by fusing myeloma and antibody-secreting cells isolated from different 
species, but the number of viable hybridomas increases dramatically when closely related 
species are used. Therefore, fusions are normally done with cells from the same species. 
Theoretically species such as rats and rabbits could be used for fusion, but today BALB/c 
mice and myeloma cell lines from BALB/c mice are most commonly used. Commercial 
breeding facilities ensure access to animals that are disease free and genetically 
homogeneous.  Mice are convenient to handle, inexpensive, and readily produce the 
requisite number of splenic lymphocytes required for a fusion. Today a broad range of 
myeloma cell lines is commercially available, and all commonly used mouse strains can 
serve as successful fusion partners with derivates of BALB/c myelomas. If the 
lymphocytes are obtained from a BALB/c mouse, the hybridoma will carry only 
histocompatibility antigens of BALB/c mice and therefore will be able to grow in the 
peritoneal cavity of BALB/c mice. After the immunization of the mice and testing for an 
immune response, the mice are sacrificed in order to use their splenic lymphocytes as one 
fusion partner. Theoretically any fusogen can effect this cell fusion, but in practice 
hybridoma fusion became routine after the introduction of PEG by Pontecorvo (1975). 
PEG fuses the plasma membranes of adjacent myeloma and/or antibody secreting cells, 
forming a single cell with two or more nuclei. The nuclei are retained until the nuclear 
membranes are dissolved prior to mitosis. During mitosis and further rounds of cell 
division a different set of chromosomes is delivered to daughter cells and chromosomes 
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can be lost. If one of the chromosomes that carries a functional, rearranged 
immunoglobulin heavy- or light chain gene is lost, the daughter cell will be unable to 
produce the desired antibody. Prior to use hybridomas are cloned three times. Each 
cloning is done from a single cell to ensure that all progeny are descendants of one 
hybridoma cell and, therefore, identical so that truly monoclonal antibodies are produced. 
  In this study BALB/c mice were immunized with 50µg of nsp1 bacterial fusion 
protein in Freund’s complete adjuvant and boosted with 50µg of nsp1 bacterial fusion 
protein in Freund’s incomplete adjuvant. All 3 mice immunized with nsp1 mounted a 
strong and readily detected immune response after the first boost, as proven by western 
immunoblotting and IFA. The fact that sera from all immunized mice reacted with the 
nsp1 protein shows clearly that the chosen protein is a good immunogen. All mice 
immunized with nsp2 and nsp4 converted to seropositive after the final boost, but overall 
the immune response was weaker compared to nsp1. The EAV protease domains are 
located in nsp1, 2 and 4 and well conserved. Nsp1 and nsp2 both have been characterized 
as papainlike cysteine protease (Snijder and Meulenberg, 1998). Nsp2 has been proposed 
to belong to a new subgroup of viral cystein proteases for its number of unique 
properties, whereas nsp4 is a member of a rare group of proteolytic enzymes. Nsp1 seems 
to be the best-researched nsp of EAV (Ziebuhr et al., 2000) and well conserved (Snijder 
and Meulenber, 1998) and therefore was chosen for the production of MAbs and the 
further use in the ELISA. To evaluate the potentiale of nsp’s, MAbs to nsp2 and 4, as 
well to the other nsp’s, and testing of there possible use in a c-ELISA should be 
conducted in further studies.   
 
7.2 Production of MAbs to the M protein 
Despite the fact that similar approaches were used for the immunization of mice 
with the nsp1 and the M-proteins of EAV, only mice immunized with nsp1 produced 
detectable antibodies that led to the successful production of protein-specific MAbs. 
Numerous factors determine the success of MAb production. Theoretically any structure 
can be recognized as an antigen. But only proteins can engage the T-lymphocytes 
required for immunologic memory and therefore only proteins induce a fully developed 
adaptive immune response. Immunological memory is produced following initial contact 
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with an antigen, and the sensitized individual is now primed to mount a potent immune 
response after challenge with the same antigen. Further contact with the same antigen 
leads to an increasingly intense immune response. Hyperimmunisation is the repetitive 
injection with an antigen to achieve a heightened state of immunity. The 
hyperimmunisation of mice in order to receive an immune response to a specific antigen 
is the first of many steps in the attempt to produce murine MAbs. The immunogenicity of 
a substance depends on a broad range of different factors, both antigen and host factor 
dependent. Antigen dependent factors include the molecular size, complexity, chemical 
composition and the susceptibility to antigen processing and presentation (Harlow et al., 
1988). In general, the larger the mass of an antigen, the more immunogenic it is. Proteins 
with a mass approaching 100 kDa tend to be most immonogenic. In general, substances 
with a molecular mass less than 5-10 kDa are poor immunogens; however a few 
substances with a molecular mass less than 1 kDa have proven to be immunogenic 
(Kuby, 2003). The genetic constitution of an immunized animal influences the degree and 
the type of immune response that the animal manifests. Hugh McDevitt demonstrated 
that inbred mouse strains differ in their response to a synthetic polypeptide immunogen 
(Kuby, 2003).  
Many proteins are poorly or non-immunogenic when administered alone, and a 
variety of factors can enhance the immunogenicity of a protein. The immunogen dosage, 
route of administration and the presence of adjuvants can influence immunogenicity. 
Optimal immunization often is achieved with intermediate doses of antigen that is 
administered either subcutaneously or intraperitoneally in a denatured form along with 
adjuvant. Freund’s complete and incomplete adjuvants remain popular for this purpose. 
Freund’s complete adjuvant is an oil-water emulsion that includes non-viable 
mycobacterium. The adjuvant delays the release of the antigen and enhances its uptake by 
macrophages. In addition, the dead mycobacteria co-stimulate the macrophages. To avoid 
the possible risk of an allergic reaction of the immunized animal and the sudden death 
through shock, Freund’s complete adjuvant is only used for the first immunization and 
incomplete Freund’s adjuvant is used for all subsequent immunizations (Harlow et al., 
1988; Kuby, 2003). 
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For the advantages of intraspecies partners for fusion, and the specific advantages 
of BALB/c mice and myeloma cell lines derived from BALB/c mice see 6.2 .  
In this study two sets, each of three mice, were immunized with 2 different 
peptides, M88 and M145. None of the mice immunized with the M peptides showed a 
detectable reaction, whereas mice immunized with nsp1 mounted a strong immune 
response. This suggests that the lack of response to the M protein was not a consequence 
of the immunization protocol, rather that the antigen was not presented in optimal format 
for processing and/or presentation.   
Although the mice used for production of nsp1 and M protein-specific antibodies 
were immunized with slightly different quantities of antigen, it is likely that differences 
in processing and presentation of the various antigens are responsible for differences in 
the immune response of mice to them. Specifically, the M protein is an unglycosylated 
protein that spans the membrane of the EAV three times and only a very short region (10-
18 amino acid residues) is exposed on the virion surface. Mice immunized with a 
recombinant Venezuelan equine encephalitis virus (VEE) vector that expresses the M-
protein of EAV mounted an immune response to the EAV M protein, but for uncertain 
reasons MAbs also were not successfully produced by fusion of splenic lymphocytes 
from these mice (Balasuriya et al., 2000). In contrast, rabbits were successfully 
immunized with 10mg of the M145 peptide (MacLachlan et al., 1998), which shows that 
different species can react differently to the same antigen. Efforts to develop MAbs to the 
M protein of other arteriviruses also have frequently been unsuccessful, whereas MAbs 
readily have been produced to the GL and N proteins of these same viruses (Drew, 2000,; 
Nelson et al., 1999; van Nieuwstadt et al., 1996; Yang et al., 2000). 
Due to the lack of MAbs against the M-protein a polyclonal anti-M serum from a 
rabbit (MacLachlan et al., 1998) was used in the c-ELISA we developed. Polyclonal sera 
contain antibodies of different specificity. Antibodies generated after a natural immune 
response or after immunization are a mixture of molecules of different specificities and 
affinities. Numerous antibodies are produced to different epitopes on the immunizing 
antigen, but even antibodies directed at a hapten with a single antigenic determination can 
be heterogeneous. With the help of affinity chromatography polyclonal antisera can be 
purified, but they still may include minor populations of antibodies that can give cross-
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reactions. Thus, each polyclonal antiserum is likely different from other antisera to the 
same antigen, even if it is produced the same way using the same materials.     
 
7.3 Development of a d-ELISA using the nsp1 MAb 
ELISA is an exquisitely sensitive and economic method for the detection of either 
antigens or antibodies. It is now widely used as an immunological assay for detection of 
protein-specific antibodies since large numbers of tests can be performed in a relatively 
short time. There are distinct variations of the ELISA for detection of protein-specific 
antibodies. D-ELISAs measure the binding of antibody directly to an antigen. Thus plates 
are coated with the target antigen, and the binding of the primary antibody is quantitatet 
usinga secondary antibody labeld with an enzyme. The enzyme coupled to the labeled 
secondary antibody converts a colorless substrate into colored reaction product.  
Development of M and nsp1 protein-specific ELISAs required coating antigen 
that contained both structural and non-structural EAV proteins. Purified whole virus 
preparations obviously lack non-structural EAV proteins (Pesch et al, 1998). An ELISA 
that incorporates baculovirus expressed protein cocktails as antigen was described by 
Hedges et al. (1998). This cocktail contains multiple EAV structural proteins but lacks 
the non-structural viral proteins, thus lysates of EAV infected BHK-cells that contain all 
structural and non-structural EAV proteins were used as coating antigens for the ELISA.  
The EAV replication cycle leads to the first release of progeny virus after 6 to 8h 
and peaks between 12 and 20h post infection in BHK-cells (Balasuriya, 1996). Thus 
EAV-infected BHK cell lysates were harvested at 12-hour intervals after infection and 
were evaluated by checkerboard titration to determine the optimal antigen concentration.  
Highest readings were obtained with antigen collected at 48 and 60 hours post infection, 
which represents approximately 4 replication cycles.  
After checkerboard titration of MAb 12A4 against different antigen dilutions, a 
combination of an antigen dilution of 1:10 with MAb 12A4 (4µg/ml) was determined to 
be optimal for further testing. The decision was influenced by the fact that the production 
of antigen and antibodies is expensive and timeconsuming and therefore higher dilutions 
are chosen if they lead to comparable results. An OD reading of 0.300 was deemed 
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sufficient for interpretation of the c-ELISA, for it gives a good signal and latitude for 
inter-test variation.  
 
7.4 Screening of other EAV protein specific MAbs with the d-ELISA 
A variety of EAV-specific polyclonal and MAbs were tested by checkerboard 
titration in direct ELISA using the EAV-infected cell lysate.  Affinity is defined as the 
strength of binding of one molecule to another at a single site, as occurs when an 
antibody binds an antigen. The increase in antibody binding affinity (affinity maturation) 
that occurs during immune responses reflects increased production of IgG antibody 
derived from mature B cells that have undergone isotype switching and somatic 
hypermutation. B cell maturation occurs after repeated antigen exposure, which explains 
why murine MAbs generally have high affinity to their particular antigen.  
Eighteen murine MAbs and a single polyclonal antiserum were evaluated.  
Individual antisera were specific for one of 3 EAV structural proteins (GL, M and N). 
Whereas Cho et al. (2000) recently described a GL-specific c-ELISA, the panel of 17 
MAbs against the GL protein we evaluated consistently failed, for undetermined reasons, 
to bind to the GL protein contained in lysates of EAV infected cell lysates. Balasuriya et 
al. characterized all MAbs against GL (Balasuriya et al., 1997), and he already reported 
that not all MAbs recognize the GL protein consistently in a c-ELISA using CsCl gradient 
purified virus as antigen. He concluded that seven of the MAbs recognized 
conformational-dependent neutralization determinants of the GL protein. His study shows 
that MAbs to the same antigen can have different affinities to their target. A low affinity 
to the GL protein in the virus used in this study is assumed to be the reason for the lack of 
signal. GL and M exist as a heterodimer in the EAV particles and infected cells (de Vries 
et al., 1995a; Snijder et al., 2003), thus it is likely that this heterodimer conformation 
influences presentation of the antigenic regions of the GL protein. Therefore the GL 
proteins produced through lysing infected cells may have a different antigenic 
confirmation that explains the low binding affinity of all MAbs against GL used in this 
study. 
In contrast, MAb against the N protein as well as the antipeptide serum against 
the M protein showed good signal strength. A dilution of 1:8000 for the MAb 3E2 and a 
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dilution of 1:600 for the polyclonal M-serum were determined to be optimal for further 
testing.  
 
7.5 Evaluation of the c-ELISA 
 The c-ELISA allows measuring antibody in a sample of unknown composition by 
attaching the appropriate antigen to the plate and measuring the ability of the test sample 
to inhibit the binding of a labeled specific antibody. It could also be used to measure the 
amount of antigen using an antibody attached to the plate. Due to this characteristic the c-
ELISA was selected, because crude antigen preparations can be used in the assay as the 
test quantifies only the displacement of each EAV protein-specific antibody by the test 
serum, thus it avoids the lack of specificity inherent in d-ELISAs. Specifically, binding of 
antibodies contained in the test serum to proteins other then the target EAV antigen in d-
ELISAs can produce false positive reactions. For example, false positive results can 
occur after binding of antibodies to cell culture proteins in lysates of virus infected cells 
or to the fusion partner in ELISAs that incorporate individual viral proteins that are 
expressed as bacterial fusion proteins. Crucial for the c-ELISA is the fact that the two 
antibodies compete for the same epitope on the target antigen, if not false negative results 
will occur. Even if the two antibodies from different origin bind the same epitope false 
results can be obtained if the laboratory antibody very strongly displaces the binding of 
the test sera. False positive results would occur if the known labeled antibody has a weak 
binding affinity and, therefore, can be displaced without the presence of competing 
antibodies. 
The strong signal shown by MAbs 12A4, 3E2 and the polyclonal serum against M 
in the d-ELISA made those antibodies potential candidates for a c-ELISA. All three 
antibodies were tested by c-ELISA with six positive equine sera. Only the polyclonal 
anti-M showed an inhibition of the binding of all six equine sera. Neither the MAb 
against nsp1 nor the MAb against N showed any inhibition of the positive equine sera. 
Since it was determined that both MAbs bind to their specific EAV protein, this result 
clearly shows that no competition between the antibodies in the equine serum and the 
MAbs occurred. It previously has been shown that EAV-infected horses respond 
immmunologically to the N protein, and serum from a horse previously infected with 
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EAV immunoprecipitated the nsp1 protein (Eric J. Snijder personal communication), 
suggesting that the equine antibodies and the MAbs recognize different epitopes on these 
two proteins.  
An antigen is defined as any substance, which can bind to a specific antibody. They 
therefore have the potential to generate specific antibodies, but some need to be attached 
to an immunogen in order to do so. Antigen can have more then one antigenic 
determinant (Gershwin, 1989), also known as epitopes. In addition different species often 
recognize different epitopes, and highly specific MAbs against one specific protein 
therefore not necessarily compete with antibodies from the natural host.  
 A panel of 50 positive and 50 negative equine sera was tested in the c-ELISA 
with the rabbit polypeptide serum against M. All 50 negative sera showed no inhibition, 
whereas 43 (86%) of the 50 positive sera clearly inhibited binding. Seven (14%) of the 
positive sera gave high OD readings and were classified as false negatives. Respectively 
the assay showed a specificity of 100% and a sensitivity of 86%. This result is consistent 
with earlier studies (MacLachlan et al., 1998), which showed that M is the most 
consistently recognized protein of EAV.  
As previously discussed, there are inter- and intraspecies differences in the 
immune response to individual antigens. The neutralizing epitopes of EAV are located on 
the GL protein, which is subject to a greater variation than the other viral proteins, which 
potentially complicates diagnostic ELISAs that focus on this protein. Diagnostic tests 
should have high specificity and sensitivity. The goal is to create tests that give neither 
false positive nor false negative results, although this clearly is difficult and not always 
achievable. A test specificity of 100% and a sensitivity of at least 99% are considered 
desirable although a false-negative rate of 1% is still considerable. Based on these 
criteria, the M-protein specific c-ELISA for serological detection of EAV infection of 
horses that was developed in this study would not be useful for routine diagnostic 
investigation. However, it did provide a general prediction of the equine humoral 
response to EAV as regression analysis showed a strong and significant correlation 
between the SN titers and the OD values of individual equine sera.  
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7.6 Conclusions 
The objective of this study was to better characterize the virus protein-specific 
antibody response of EAV-infected horses. The c-ELISA was selected because crude 
antigen preparations can be used in the assay as the test quantifies only the displacement 
of each EAV protein-specific antibody by the test serum, thus it avoids the lack of 
specificity inherent in direct ELISAs (Chirnside et al., 1995; Chirnside et al., 1995a; 
Cook et al., 1989; Hedges et al., 1998; Nugent et al., 2000). Despite these potential 
inherent advantages, none of the developed c-ELISAs to various EAV proteins had 
acceptable sensitivity although the M protein-specific c-ELISAs most consistently 
detected EAV antibodies in SN-positive sera.       
Previous studies of the humoral immune response of horses to EAV have focused 
on detection of antibodies to structural viral proteins (Hedges et al., 1998; MacLachlan et 
al., 1998).  Data from the present study confirm the conclusions of previous ELISA and 
Western immunoblotting studies that EAV SN-positive horse sera do not reliably identify 
the N protein.  Furthermore, the data show that although nsp1 is abundantly produced in 
EAV-infected cells (Tijams et al., 2002), and that serum from a horse previously infected 
with EAV immunoprecipitated the nsp1 protein (Eric J. Snijder, personal 
communication), a c-ELISA utilizing the MAb we developed to nsp1 was not useful in 
identifying EAV SN-positive horse sera. The M protein was confirmed by c-ELISA to be 
most consistently recognized by SN-positive sera from naturally and experimentally 
infected horses, as previously shown using both Western immunoblotting and direct 
ELISA utilizing M protein expressed from recombinant baculovirus (Hedges et al., 1998; 
MacLachlan et al., 1998). Recently, Jeronimo and Archambault (2002) also demonstrated 
that EAV-specific horse sera readily recognize the carboxy terminal region (amino acids 
88-162) of the M protein and further suggested this region might be useful for 
serodetection of EAV-infected horses. Although highly specific, the M protein-specific c-
ELISA using rabbit anti-peptide serum to the extreme carboxy terminus (amino acids 
145-162) lacks sensitivity, as does the direct ELISA which was developed using 
recombinant M protein (Hedges et al., 1998).  Murine MAbs have yet to be produced to 
the M protein of EAV, despite intensive efforts by ourselves and others (unpublished), 
thus it is uncertain as to whether the sensitivity of the assay would be improved with a M 
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protein-specific MAb rather than the M protein-specific rabbit antipeptide sera that we 
used. 
The SN test remains the gold standard for serological diagnosis of EAV infection 
of horses (Balasuriya et al., 1997; Balasuriya et al., 1998; Senne et al., 1985).  The SN 
test putatively detects antibodies to the GL protein, as this protein expresses the known 
neutralization determinants of EAV (Balasuriya et al., 1997). The MAbs evaluated by the 
direct ELISA consistently failed to bind to the GL protein contained in EAV-infected cell 
lysates, and therefore the development of a c-ELISA incorporating a GL-specific MAb 
failed.  It was previously shown that these same GL-specific MAbs bind strongly in direct 
ELISAs that incorporate purified EAV virions as antigen (Balasuriya et al., 1993), 
however purification of EAV for use as ELISA antigen is both difficult and expensive 
and thus not practical. 
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8. Summary 
  
The increasing number of equine arteritis virus (EAV) outbreaks worldwide 
suggests that equine viral ateritis (EVA) is an emerging disease.  A quick, accurate and 
reliable serological test would be invaluable in preventing future outbreaks of EVA, and 
for import/export regulation pertaining to EAV infection of horses.   
The objective of this study was to further characterize the humoral immune 
response of horses to EAV with a long-term objective of designing an improved 
diagnostic serologic test. Using a crude cell lysate of BHK-21 cells infected with the 
EAV clone 030H as antigen, direct and competitive enzyme-linked immunosorbent 
assays (c-ELISAs) were developed using monoclonal and polyclonal antibodies to 
structural (GL, N and M) and non-structural (nsp1) viral proteins. An nsp1-specific 
monoclonal antibody, MAb 12A4, was produced to facilitate development of a c-ELISA 
using this protein. All MAbs against the GL protein gave insufficient signal for further 
use in a c-ELISA; MAb 12A4, 3E2 and a monospecific rabbit anti-M serum were 
selected for use in different c-ELISAs. A panel of 50 positive and 50 negative equine 
sera, confirmed by serum neutralization (SN), was tested in the c-ELISA. Only the 
antipeptide serum against the M-protein showed inhibition of positive horse sera, 
respectively showing a specificity of 100% and a sensitivity of 86%. Regression analysis 
of OD values in the ELISA confirmed a strong and significant correlation to the SN titers 
of the same sera (r2= 0.82). 
Data obtained using the various c-ELISAs confirm that the M protein is a major 
target of the antibody response of horses to EAV. However, none of the c-ELISAs that 
were developed were as sensitive in detecting EAV-specific antibodies in horse sera as 
the existing SN test. 
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9. Zusammenfassung 
 
Die global ansteigende Zahl von Infektionen mit dem Equinen Arteritis Virus 
(EAV) lässt darauf schliessen, dass die Equine Virus Arteritis (EVA) zu den “emerging 
diseases” gezählt werden kann. Ein schneller, präziser und zuverlässiger serologischer 
Test ist notwendig zur Einhaltung von Im- und Export-Bestimmungen und damit 
unerlässlich zur Prävention zukünftiger EVA-Ausbrüche. 
Das Ziel der vorliegenden Arbeit war, einen verbesserten diagnostischen Test für 
EVA zu entwickeln, der neue Erkenntnisse bezüglich der humoralen Immunantwort von 
EAV infizierten Pferden berücksichtigt.  
Ein unbehandeltes Zelllysat aus mit EAV Klon 030H infizierten BHK-21 Zellen 
wurde als Antigen für die Entwicklung von direkten ELISAs (d-ELISA) und 
competitiven ELISAs (c-ELISA) verwendet. Desweiteren wurden monoklonale und 
polyklonale Antkörper gegen die Strukturproteine GL, N, M und ein Nicht-
Strukturprotein, nsp1, von EAV eingesetzt.  
Die Herstellung eines nsp1-spezifischen monoklonalen Antikörpers (MAb), MAb 
12A4, ermöglichte die Entwicklung eines c-ELISAs. Die gegen das GL Protein 
gerichteten MAbs wurden aufgrund unzureichender Signalgebung für einen Einsatz in 
einem c-ELISA ausgeschlossen. Letztendlich wurden MAb 12A4, 3E2 (anti-N) und ein 
monospezifisches Kaninchen anti-M Serum für den Einsatz in den verschiedenen c-
ELISA Testmethoden ausgewählt. Eine Auswahl von 50 positiven und 50 negativen 
Pferdeseren, alle mittels  Serumneutralisationtests (SN) vorgetestet, wurde im c-ELISA 
eingesetzt. Eine Inhibition von positiven Pferdeseren konnte lediglich mit dem gegen das 
M-Protein gerichteten anti Peptid Serum erzeugt werden. Dabei wurde eine Test-
Spezifizität von 100% und eine Sensivität von 86% ermittelt; eine Regressionsanalyse 
der OD-Werte zeigte eine starke und signifikante Korrelation (r2 = 0.82) zu den Titern 
der Serumneutralisationstests derselben Seren. Die experimentelle Auswertung der Daten 
verschiedener c-ELISA Testmethoden deutet darauf hin, dass das M-Protein ein 
Hauptziel der Immunantwort von EAV infizierten Pferden ist. Dennoch erreichte keine 
der entwickelten c-ELISA Testmethoden eine mit dem SN-Test vergleichbare 
Sensitivität.  
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